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ABSTRACT OF DISSERTATION

THERMODYNAMICS AND KINETICS OF THE THREE-WAY JUNCTION OF
PHI29 MOTOR PRNA AND ITS ASSEMBLY INTO NANOPARTICLES FOR
THERAPEUTIC DELIVERY TO PROSTATE CANCER
The emerging field of RNA nanotechnology necessitates creation of functional
RNA nanoparticles, but has been limited by particle instability. Previously, it was found
the three-way junction (3WJ) of the Phi29 DNA packaging motor pRNA was found to be
ultra-stable and assemble in solution without the presence of metal ions. The three-way
junction is composed of three short oligo RNA strands and proven to be thermodynamically
stable. Here the assembly mechanism, thermodynamic and enzymatic stabilities, and
kinetics are examined in order to understand the stability behind this unique motif.
Thermodynamic and kinetics studies found that the pRNA 3WJ formed out of three
components at a rapid rate creating a single-step three component collision with a lack of
dimer intermediate formation while being governed by entropy, instead of the commonly
seen enthalpy. Furthermore, the pRNA 3WJ proved to be stable at temperatures above 50
°C, concentrations below 100 pM, and produced a free energy of formation well below
other studied RNA structures and motifs. With the high stability and folding efficiency of
the pRNA 3WJ, it serves as an ideal platform for multi-branched RNA nanoparticles
constructed through bottom-up techniques. RNA nanoparticles were constructed for the
specific targeting of prostate cancer cells expressing Prostate Specific Membrane Antigen
(PSMA) by receptor mediated endocytosis through the addition of an RNA aptamer; and
the delivery of anti-miRNA sequences for gene regulation. The resulting nanoparticles
remained stable while showing highly specific binding and entry in PSMA positive cells
through cell surface receptor endocytosis. Furthermore, the entry of the nanoparticles
allowed for the knockdown of against onco-miRNAs. Nanoparticles harboring antimiRNAs led to the upregulation of tumor suppressor genes, and signaling of apoptotic
pathways. These findings display RNA nanotechnology can result in the production of
stable nanoparticles and result in the specific treatment of cancers, specifically prostate
cancer.

KEYWORDS: RNA Nanotechnology, Phi29 Packaging Motor, Thermodynamics,
Kinetics, Prostate Cancer
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Chapter 1: Introduction and Literature Review
BRIEF SUMMARY:
Chapter 1 begins this thesis with an overview on the creation and necessitation of
RNA nanotechnology. First the promise of RNA interference technology is examined,
and how RNA nanotechnology improves the delivery of RNA therapeutics for the
treatment of cancers and viral diseases. Next the importance of particles stability is
looked at by examining thermodynamic and kinetic properties. Finally, these parameters
are discussed in the design of RNA nanoparticles.
Chapter 2 looks at the thermodynamic stability of the pRNA-3WJ. Here the
stability of the RNA motif is compared to its DNA and chemically modified 2’-Fluoro
RNA species in effort to stabilize the motif against nucleases and improve the
thermodynamic stability and parameters. It was found the 2’-Fluoro RNA not only
provides nuclease resistance, but also enhance the thermodynamic properties by
increasing the melting temperature and decreasing the change in Gibbs free energy.
Through these tests, it was found that the pRNA-3WJ forms through a rapid association
in which no dimer intermediate could be detected and the formation of the RNA species
assemble by an increased change in entropy over the DNA species, compared to the
commonly seen more favorable change in enthalpy and decrease in entropy.
Chapter 3 studies the assembly mechanism of the pRNA-3WJ is examined more
in-depth. Primarily using surface plasmon resonance, kinetic parameters of the pRNA3WJ are elucidated resulting in the discovering the assembly mechanism of the pRNA3WJ. It was found the 3WJ formed through a two-step association, forming an
intermediate that then instantly resulted in the recruitment of the third RNA strand, thus
1

creating the pRNA-3WJ at an unobservable rate. Additionally, it was discovered the
pRNA-3WJ relied on each of its helical regions for either the rapid formation or the long
lasting stability. This rapid and unique assembly mechanism proves the pRNA-3WJ
reactants forms into the 3WJ with a high efficiency and yield that can be translated to the
production of RNA nanoparticles.
Chapter 4 takes the findings from the second and third chapters and applies them
to the production of RNA nanoparticles for the targeting and treatment of prostate cancer.
Stable RNA nanoparticles were constructed using the pRNA-3WJ as the central core with
an RNA aptamer to target Prostate Specific Membrane Antigen (PSMA) and anti-miRNA
sequences for therapeutic treatment. It was found that the resulting RNA nanoparticles
were able to specifically bind and enter PSMA expressing cancer cells, delivering the
anti-miRNA sequences. This specific delivery led to knockdown of the miRNAs, thus
upregulating tumor suppressor genes and sensitizing cells to apoptosis. These findings
demonstrates the versatility and ability of the pRNA-3WJ as RNA nanoparticles that has
previously been unobtainable.
Chapter 5 briefly summarizes the major findings and advancements of RNA
nanotechnology discussed in this thesis dissertation. Furthermore, the future direction of
this work is described providing a prospective on research that is still needed to fully
prove the benefits of RNA nanotechnology. Finally, the current state of RNA
nanotechnology is discussed looking at the major hurdles that have been solved and look
at how the recent advancements can propel RNA nanotechnology into the cancer
therapeutic spotlight.

2

HYPOTHESIS:
The 3WJ motif from Phi29 bacteriophage packaging RNA (pRNA) provides a
stable RNA scaffold for the construction of nanoparticles for the treatment of cancers.

INTRODUCTION:
Nanotechnology and drug delivery
First realized by Richard Feynman in 1959, the field of nanotechnology is the
control of materials in design, interactions, and function at the atomic and molecular level
(1). It wasn’t until the 1980s when the principles of nanotechnology were put into
practice by K. Eric Drexler; when he proposed the building of nanomachines capable of
self-replication (2). Nanotechnology was later defined by the National Nanotechnology
Initiative to be the manipulation of materials with the size range of 1 – 100 nm in size. As
technologies advanced through the years, the field of nanotechnology grew as scientists
were able to image and analyze the particles using techniques such as atomic force
microscopy (AFM), transmission electron microscopy (TEM), and scanning tunnel
microscopy (STM). Nanoparticles have since been created from a wide array of materials
such as lipids (3); polymers (4); proteins and peptides (5); viruses and viral components
(6); carbons (7); heavy metals, such as gold (8) and silver (9); iron oxide (10);
deoxyribonucleic acid (DNA) (11); and ribonucleic acid (RNA) (12).
While the field of RNA nanotechnology has spread to a vast array of applications,
a currently developing and promising application is drug delivery (13,14). The principle
of nanotechnology in drug delivery is to increase the bioavailability of drugs or
3

therapeutic agents (15,16). As numerous drugs currently being developed have solubility
(17) or toxicity issues, their practical application for the treatment of diseases are truly
limited. Nanoparticles have been proven to link, uptake and attach to said drugs in hopes
of increasing delivery to targeted diseases (18-23). Nanoparticle formulations have been
shown to increase the solubility of difficult drugs; deliver a high dosage of therapeutics at
desired sites through drug release mechanisms, such as pH sensitive binding and release
particles (24-28); and provide specific targeting to cells through the use of peptide (2931) and aptamer ligands, RNA motifs that have been specially designed and selected for
binding to chemical and protein substrates such as cell surface receptors (32,33). As a
result, toxicity is decreased as a smaller total drug concentration is delivered in vivo, all
while a higher local dosage is delivered to targeted sites.
While each nanoparticle material provides its own set of advantages and
disadvantages; as a whole nanotechnology is still a developing field that is still working
on overcoming hurdles to produce a more perfect drug delivery vehicle and improve on
current standards of pharmaceutics. Lipid based nanoparticles allow for high drug or
therapeutic loading and encapsulation and allow for high delivery of payloads through
membrane fusion with cells while remaining nontoxic and not producing immune
responses (34,35); however, such nanoparticles have shown issues with thermodynamic
stability causing release of payload prematurely (36) and issues with production
reproducibility resulting in the production of inconsistent products (37). Similarly
polymer based nanoparticles allow for high levels of therapeutic encapsulation (38);
however, polymers display a significant increase in thermodynamic stability and can
easily be functionalized on the surface for targeting abilities (39). Yet polymers still show
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issues with batch reproducibility and have shown issues with solubility and
bioavailability. Biologically derived nanoparticles such as viruses, viral components and
proteins and peptides have issues of producing immune responses and creating certain
levels of toxicity. Yet targeted delivery allows for a lower overall dose while having a
high accumulation in targeted tissues (40-43). Inorganic nanoparticles such as carbon
structures and metal ions can be created with high reproducibility with a lower cost than
most nanoparticles. Furthermore, these particles can be functionalized through chemical
modifications; however, their high accumulation in healthy organs such as kidneys,
lungs, and liver result in high toxicity and limit their overall ability for therapeutic
delivery. DNA nanostructures are constructed with defined shape, size, and stoichiometry
(44-46) and can achieve targeted delivery with the functionalization of DNA aptamers
(47,48); yet the overall low thermodynamic stability of DNA nanoparticles limits their
ability for in vivo applications. Additionally, positively charged nanoparticles such as
metal ions, some polymers, proteins have overall positive charges that allows for
endosomal escape through proton sponge effect (49), yet this positive charge allows for
passive binding to negatively charge cells membranes, leading to non-specific binding to
healthy tissues producing toxicities.
The promises of RNA interference in therapeutics
The discovery of RNA interference (RNAi), in which RNA sequences create gene
regulation by the binding and degradation of messenger RNA, by Craig Mello and
Andrew Fire in 1998 lead to revolutionary work in the RNA field (50). Their discovery of
RNAs in C. elegans proved that RNA was not simply a temporary intermediate of the
production of proteins from DNA through transcription and translation, but that RNA
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plays and essential role in cell functioning and processing. Additionally the discovery of
functional RNA, dismissed the myth of “junk DNA and RNA.” Their work discovered
microRNA (miRNA), a naturally occurring RNA loop on messenger RNA (mRNA) that
is processed into single stranded RNA that is then able to bind and silence several
mRNAs resulting in gene regulation. Since Mello and Fire’s original work, studies of
miRNA and its role in gene regulation, cell functionality, and role in disease development
has exploded into a large field of study. Additionally the development of small interfering
RNA (siRNA) by David Baulcombe (51) in plants and in mammalian cells by Thomas
Tuschl (52,53) provided a novel method of gene regulation and proposed method of
controlling cell growth, gene regulation, and even apoptosis (54-57). Much like miRNA,
siRNA silences mRNAs and genes however, the sequences are synthetic and designed for
a single gene while miRNA targets several genes.
The discovery of RNAi has heightened interests in using the short RNA
sequences for RNA therapeutics (50). Many efforts have been made in delivery RNAi
therapeutics for the treatment of diseases, most notably in cancers and viral infections
(54-62). However, trials of testing the delivery of naked siRNA led to disappointing
results, as the short RNA sequences were either quickly degraded by commonly
occurring RNases or displayed short half-lives of only 15-45 minutes by being excreted
through the liver due to their small size (63-65). Nanotechnology has since gained a large
interest in the delivery of RNAi therapeutics in various disease states due to the principles
of nanoparticles increasing the size of the siRNA or miRNA and protecting the RNA
strands from nuclease degradation (54-62). Furthermore nanoparticles have proven
beneficial in delivering payloads to cancer tumors due to their ability to pass through
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leaky blood vasculature creating the enhanced permeability and retention (EPR) effect,
while remaining large enough to stay in circulation in the body (66-70).
Recently, a new attractive RNAi therapeutic has been developed for the treatment
of cancers. miRNAs have been shown to play a large role in cancer development whether
they are either overexpressed or reduced in expression (71-77). Modified locked nucleic
acid (LNA) sequences have been selected and developed to bind to miRNA seed-regions
(78), resulting in the inactivation and silencing of microRNAs. This can serve as
potentially powerful therapeutic to target over expressed miRNA with cancers known as
oncomirs. While these anti-miRNA LNAs are too small to be delivered directly, as they
would be immediately be cleared from the body, efforts have been made in delivering
such LNAs through the incorporation onto nanoparticles. Several technologies have
encapsulated an anti-miRNA 21 strand into polymer based nanoparticles for the delivery
to triple negative breast cancer (79), lipid nanoparticles to glioblastroma (80) and lung
cancer (81), and a lipid-gold nanoparticle hybrid delivered to androgen independent
prostate cancer (82). Additionally anti-miR21 has been placed onto RNA nanoparticles
for the specific delivery and treatment of breast cancers (83). Additionally polymer
nanoparticles have been used to deliver an anti-miRNA 10b sequence to breast cancer
(79) and metal nanoparticles also delivered anti-miR10b to breast cancers (84). Cheng et.
al. used a pH sensitive peptide nanoparticle system for the specific delivery of antimiR155 to lymphoma without the accumulation of nanoparticles in healthy tissue (85).
The wide array of research being completed on several cancer lines and several oncomirs
indicated the power of the anti-miRNA LNAs and the current interest in the RNAi field.
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Birth of RNA nanotechnology
The concept of RNA was first proven in 1998 (12) through the creation of a
hexameric ring of packaging RNA (pRNA) on the Phi29 bacteriophage for the packaging
of viral DNA into the procapsid of virus during replication. The discovery and
development of inter-molecular interactions between pRNAs, deemed loop-loop
interactions, proved specific control the looped sequences forming the inter-RNA
interactions. These interactions allowed for the assembly of the pRNA ring and the
number of pRNA copies in the ring could therefore be controlled. pRNA is a ~120 base
pair (bp) RNA structure that serves as a binding sight between the Phi29 connector pore
that allows for the packaging of the genome into the virus procapsid and the gp16
ATPase. RNA is an ideal platform for the creation of nanoparticles due to its beneficial
characteristics listed below. RNA is primarily composed of four nucleotides, adenine(A),
cytosine (C), guanine (G) and uracil (U); giving RNA the simplistic design of DNA. This
concept allows for the construction of molecules with easily predictable structures with
defined shapes and stoichiometry (12,86-88). However, unlike DNA, ribonucleic acids
allow for non-canonical base pairing, or pairing between non-Watson-Crick pairs such as
A-G, as well as RNAs contain bulges, loops, and interactions between bases on separate
strands creating

what is known as kissing loops (86,89,90). The diversity in base

interactions found in RNA provides a wide diversity in folding and structure much to
proteins (91).
Furthermore, with the diverse folding of RNAs brings a variety of functionalities
and actions. Traditionally, RNA is considered as a temporary intermediate of DNA for
the translation of proteins; however, it is now well understood that RNA holds many
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functionalities within the body and non-coding RNAs play important roles through gene
expression and cell functionality. Such examples of these RNAs are pRNA of the Phi29
bacteriophage, ribozyme (92-94), riboswitch(95,96), small interfering RNA (siRNA) (9799), micro RNA (miRNA) (100-102), ribosomal RNA (rRNA) (103-106), small nucleolar
RNAS (snoRNA) (107-109), small nuclear RNA (snRNA) (110,111), and RNA aptamer
(32,33). The simplistic design, yet diverse structuring and functionality of RNA has made
it attractive to many scientist for applicational uses such as the treatment of cancers and
viral infections. Due to the nature of RNAs, RNA nanotechnology provides several
benefits over competing nanotechnologies utilizing proteins, DNA, and polymers
(91,112): 1) as stated earlier, RNA can be produced with defined shape and stoichiometry
as well as high reproducibility (12,86-88). 2) RNA can target specific cell groups by
targeting cell surface receptors through the use of RNA aptamers, motifs that have
specifically been selected for specific binding to chemical or protein ligands, without
inducing antibody production, allowing for repeated delivery and therapy (113-115). 3)
RNA nanoparticles that have been produced have a size range of 10-50 nm, the perfect
size to be retained within the body and pass through leaky blood vessels in cancer tumors
by Enhanced Permeability and Retention (EPR), as well as cell membranes by cell
surface receptor endocytosis (66-68). 4) RNA can be created to harbor multiple
therapeutic elements by utilizing branch scaffolds (98,116-119) and bottom-up
construction (86,97). 5) RNA is known to have a higher thermostability over DNA with a
higher melting temperature and more negative Gibbs free energy of formation (120,121).
6) RNA materials have gained FDA approval due to their known exact known size and
chemical makeup compared to other nanotechnologies (91).
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RNA scaffolds
Since the original development of the tunable Phi29 packaging RNA (pRNA)
nanoparticles several other RNA based nano-platforms have been produced. The Guo lab
has continued their work on the Phi29 pRNA system, most notably with the three-way
junction (3WJ) motif composed of three short oligo strands that has been proven to be
thermodynamically stable (87,122). The 3WJ has since been used as a building block to
produce the pRNA X-way motif (123); varying shapes including triangles, squares, and
pentagons (124-127); and further 3D arrays from the resulting shapes. Additionally, Luc
Jaegar first developed a building block coined as TectoRNAs that utilized looped regions
between RNA strands for base pairing to build nanostructures (89). From the TectoRNAs
a variety of structures have been built including tectosquares, Jigsaw puzzles, nancubes,
and nanorings (88,128-131). Similarly Thomas Hermann has developed a self-assembling
square composed of an RNA backbone (132) and Saito’s group has created a triangle
RNA scaffold (133). Recently, Paula Hammond has developed an RNA microsponge that
is capable of uptaking siRNAs for delivery (38,134). These RNA nanoparticles have laid
the foundation of scaffold that can be used for the inclusion of RNAi components for the
treatment of diseases (38,87,123,134-142).
Elucidation and modeling of thermodynamic parameters of nucleic acids
The formation of RNA nanoparticles from multiple strands is depended on the
formation of base pairing between or within singular strands. This assembly process is
governed by thermodynamics, which has since been proven to be sequence dependent.
Extensive studies have been completed looking at the thermodynamic contributions of
each RNA and DNA sequence, which in turn developed nearest neighbor parameters.
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Thermodynamic parameters during the folding and melting of RNA and DNA
duplexes has been long studied using various sequences. Originally, duplex interactions
of DNA was studied to derive thermodynamic parameters that lead to the modeling of
nucleotide contributions in folding energy landscapes (143,144). This work resulted in
the development of nearest neighbor predictions, in which thermodynamic parameters
could be predicted by the sequence of DNA. RNA models were then created in a similar
fashion (145-147), that then led to the studying of RNA/DNA hybrid duplexes (120).
While these initial studies were very informative, the predictive models were limited to
duplex structure, whereas RNA is known to fold into diverse structures with branches,
bulges, and looped regions. In looking at several junctions and looped regions, Doug
Turner was able to elucidate thermodynamic energies for RNA three- and four-way
junctions (3WJ, 4WJ) (148).
From these fundamental studies, thermodynamic experiments were expanded to
study the overall thermostability between nucleic acid species. Lesnik and Freier first
compared 14 sequences ranging from 9 up to 21 base pairs in length composed of DNA
and RNA, along with each of the hybrid structures (RNA/DNA duplex) (149). From their
studies, it was found that 13 of the 14 RNA sequences displayed melting temperatures,
Tms, higher than the corresponding DNA sequences. In nucleic acid studies, melting
temperature is defined as the temperature in which 50 % of the nucleic acid strands are
assembled into motif and 50 % are in single strand states. Furthermore, the same 13 of 14
sequences displayed the more favorable, more negative Gibbs free energy (ΔG°). The
ΔG° is the release (negative) or consumption (positive) of energy by the nucleic acid
strands when folding into their motifs; a negative value indicated energy is being released
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and is therefore spontaneous, the lower the value the more spontaneous the reaction will
be. The one exception to the study was a sequence with a repeat of A-T base pairing.
Several additional studies have been published on comparing thermostabilities and
folding energy levels of RNA and DNA sequences (150-153). Again from each of these
studies, it was concluded RNA produced a more negative ΔG° and more positive Tm over
the same DNA sequence. The widespread studies of relative stability of RNA has shown
it provides a more favorable folding landscape by assembling more spontaneously and
displaying a higher overall stability with the increased melting temperature over DNA.
Furthermore, from the derived nearest neighbor calculations and studying known
RNA motifs and structures, several computational programs have been developed to
predict the folding of RNA motifs and their relative energy landscapes for both folding
and denaturing. Using energy landscape predictions, programs such as mFold (154),
UNAfold (155), and RNAfold (154,156) have been developed to predict the secondary
structuring of RNA motif leading to predictive base pairing. Moving from secondary
interactions to tertiary and quandary predictions has proven to be much more difficult.
RNA structural studies have thus been conducted by Eric Westhof (157-160), Neocles
Leontis (89,90,157,161-163), and David Lilley (164-167). Such studies have created
databases of RNA motifs that are now used for the predictive folding and interactions of
RNA sequences (168-171).
Importance of thermodynamics and kinetics in RNA nanotechnology
Due to the fact that RNA nanoparticles rely on hydrogen bonding between base
pairing to keep the nanoparticle together, folding thermodynamics and kinetics are
imperative for nanoparticle stability. Together kinetics and thermodynamics describe the
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ability and speed of the RNA motif or nanoparticle to fold, along with its overall stability.
In nanoparticles design, the folding mechanism is crucial, in that a central motif that folds
rapidly and spontaneous with favorable thermodynamics is desired. Additionally one
must examine the folding energies to examine the concern of side products is
minimalized, in order to produce as pure of a product as possible. In nanotechnology,
creating particles of defined shape and size with high reproducibility is paramount in
going through FDA approval. Additionally particle thermodynamic stability is an
absolute key in nanoparticle design and construction. In looking at in vivo applications,
nanoparticles will be subjected to dilute concentrations and elevated temperatures of the
body of 37 °C. These conditions will test the stability of base-paired RNA motifs in
which dissociation is not only unacceptable, but a serious concern. Nanoparticles must be
tested to be stable at temperatures and concentrations that will be seen in vivo to ensure
stability of the particle and therapeutic as well as proper delivery of the therapeutic agent
to the target. As shown above through the nearest neighbor modeling, thermodynamic
stability of RNA duplexes and structuring is highly dependent on both the sequence and
oligo length. Therefore full characterization of folding and stability of nanoparticles is
necessary for the advancement of the field to in vivo applications.

Copyright © Daniel William Binzel 2016
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Chapter 2: Thermodynamic Analysis of Phi29 pRNA-3WJ
This chapter was reproduced (with some modification) with permission from Binzel DW,
Khisamutdinov EF, Guo P. “Entropy-Driven One-Step Formation of Phi29 pRNA 3WJ
from Three RNA Fragments.” Biochemistry, 2014. 53 (14), 2221-2231. DOI:
10.1021/bi4017022. Copyright 2014 American Chemical Society. Special thanks to Dr.
Emil F. Khisamutdinov for help in preparation of data for figures 2.3, 2.5, and 2.6A and
Zhengyi Zhao in preparing figure 2.1A.

INTRODUCTION:
Since the proof-of-concept in 1998 (12), RNA nanotechnology has been emerged
as a popular field (86,91,128,157,159,172-175). RNA has the simplistic chemical
characteristics of DNA, and the complex folding and functionality of proteins (91). These
attributes make RNA an ideal candidate for creating nanoparticles with diverse
functionalities for targeting and treating cancer tumors and viral infections, as well as
other applications in nano devices (12,38,86,87,118,123,176-182). RNA nanotechnology
in therapeutics provides many advantages over current technologies (91,112): 1) RNA
can be produced with defined shape and stoichiometry as well as high reproducibility
(12,86-88). There are many modified nucleosides within RNA, but it is primarily
composed of only four nucleic acid bases, allowing for simplicity in structure and
predictable interactions between molecules and formation of structures. 2) RNA can
target specific cell groups by targeting cell surface receptors through the use of RNA
aptamers that function like protein or chemical ligands (113-115). These structures do not
induce antibody production, allowing for repeated delivery and therapy (113). 3) RNA
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nanoparticles that have been produced have a size range of 10-50 nm (66-68), the perfect
size to be retained within the body and pass through leaky blood vessels in cancer tumors
(69,183), as well as cell membranes by cell surface receptor endocytosis (68). 4) RNA
can be created to harbor multiple therapeutic elements by utilizing branch scaffolds
(98,116-119) and bottom-up construction, the development of nanoparticles through the
design of subcomponents that then are used to assemble into the final product (86,97).
Even with these advantages, RNA nanotechnology has been hindered because of the
instability of RNA itself, specifically in vivo. Dissociation of complex without covalent
bonds is an intrinsic property of molecules, e.g. RNA molecules, that are
thermodynamically instable in nature (120,146,149,150,184-188).
When RNA nanoparticles are delivered systemically to the body, the particles will
exist in low concentrations due to dilution by circulating blood. Only those RNA particles
that do not dissociate at low concentrations are feasible for therapeutic purposes that
require systemic delivery. Furthermore, RNA can easily be degraded and cleaved by
RNase found throughout the human body (112). Chemically modified nucleotides have
been developed to combat the nuclease degradation. Specifically, 2′-F modified
nucleotides have been shown to keep the original folding and functionality of the RNA
molecules while significantly increasing the half-life (189). In order to overcome the
instability issues and push the RNA nanotechnology field to progress further, a stable
platform needs to be produced that can remain stable at low concentrations and high
temperatures while resisting RNase degradation (87,123,177).
Recently, a three way junction motif (3WJ) in the packaging RNA (pRNA) of the
bacteriophage Phi29 dsDNA packaging motor was found to be ultra-stable (87). The
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pRNA-3WJ produced a melting curve indicative of a low Gibbs free energy (ΔGº), the
total energy that is either released or consumed by a system through a reaction or work,
thus determining spontaneity of the system (190,191), as well as a high melting
temperature (Tm). It has also been elucidated that the 3WJ is stable in ultra-low
concentrations, as well as in 8 M urea, a common denaturing agent for nucleic acid
structures. This junction serves as the central core of the pRNA and links the helical
domain (192) to the interlocking looped regions (193), and allows for intermolecular
interactions with other pRNA molecules (Fig. 2.1). The core can be formed from three
individual RNA oligos with a high efficiency without the presence of metal ions, as many
RNA motifs require the presence of metal ions, like Magnesium, for folding, assembly,
and stabilization. Therefore, the pRNA-3WJ shows an initial sign of higher stabilization
than many RNA motifs. It has been found that this junction can incorporate RNA
functional moieties, such as receptor-binding aptamer (32,33), siRNA (97-99), ribozyme
(92-94), miRNA (100-102), or riboswitch (95,96). Additionally, the resulting structures
have the ability to keep the strong folding of the core, while retaining the functionality of
the conjugated RNA moieties (87). Even with the strong stability of the 3WJ, it is still
very much susceptible to degradation by RNases; therefore, chemical modifications to the
RNA are required (64,186,195). The effects on the thermodynamic stability of the
pRNA-3WJ core, though, are still unknown.
Previously, thermodynamics of nucleic acids and their folding properties have
been studied; however, the majority of the studies have been completed on RNA and
DNA

duplex

sequences

(120,143,144,146,149-151,153).

An

estimation

of

thermodynamic parameters for RNA 3- and 4WJ have been surmised (148) from studies
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Figure 2.1. Background information for motor pRNA, pRNA three-way junction
(3WJ). (a) The side-view of the hexametric structure of Phi29 DNA-packaging
motor(194). Two bottom are side-view and top-view of the hexameric pRNA derived
from X-ray crystallography(122). (b) Predicted secondary structure of the Phi29
packaging RNA (pRNA) with the 3WJ motif outlined and the pRNA-3WJ.
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completed using two piece designs by incorporating looped regions between helical
branches. A gap has remained within the thermodynamic studies of nucleic acids
regarding elucidating thermodynamic characteristics of multi-branched structures, i.e.,
multi-stranded motifs. Additionally the understanding of chemical modifications to the
RNA backbone on RNA junctions has remained a mystery, and untouched. In order to
understand the thermodynamic characteristics of such structures and comprehend the
governing laws of motif folding, new methods must be developed to be able to see multistranded interactions.
Here we report the measured thermodynamic parameters for 3WJ complexes
containing DNA, RNA, and 2′-F U/C modified RNA strands (Fig. 2.1), as well as hybrid
complexes by means of comparison of their stability using a real time Polymerase Chain
Reactions (rtPCR) machine and Temperature Gradient Gel Electrophoresis (TGGE).
Results concluded that use of DNA strands weakened the structure of the pRNA-3WJ,
while 2′-F modifications strengthened the RNA motif by elevating the transition
temperatures and lowering ΔG°. More importantly, the data appears to show the 3WJ
formed in a single step without displaying presence of dimer species, showing that all
three strands of the pRNA-3WJ formed together into complex rapidly with the
intermediate product undetectable. The assembly was also revealed to be entropy driven.
MATERIALS AND METHODS:
Oligonucleotides and assembly of 3WJs
RNA, DNA, and oligonucleotides were obtained from Integrated DNA
Technologies (IDT). RNA oligonucleotides containing 2′-F U/C modification were
ordered from Trilink BioTechnologies. Assembly of 3WJs were performed by mixing
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equimolar concentration of corresponding strands in TMS (50 mM TRIS pH = 8.0, 100
mM NaCl, 10 mM MgCl2) buffer, heating to +80 °C, and slowly cooling to +4 °C at a
rate of 2.0 °C/min for a total of 37 minutes. The 3WJ formations were assayed on a 12%
native PAGE TBM running buffer (89 mM Tris, 200 mM Borate acid, and 5 mM MgCl2)
ran at 100 V at 4 °C for 90 min. Gels were stained with Ethidium Bromide (EB) and
imaged using a Typhoon (GE).
KD measurements
Apparent equilibrium dissociation constants (KD) for 3WJ formations were
determined by titration over a range of concentrations from 0.1 nM to 512 nM, as
previously described (88,196). Concentrations of the 3WJs were calculated using the
absorbance of UV light at 260 nm using a Nanodrop 2000 (Thermo Scientific) using an
extinction coefficient of 40 µg/ml and 50 µg/ml for RNA and DNA, respectively. Briefly,
fixed amounts of [32P] ATP 5′-end labeled 3WJb strands of RNA, DNA, and 2′-F
modified RNA (0.1 nM final) were mixed with variable amounts of unlabeled 3WJa and
3WJc strands RNA to make the indicated final concentration (0.1 nM to 512 nM) of each.
The resulting 3WJs were then heated to 80 °C for 3 min in TMS buffer and slowly cooled
to 4 °C. The resulting gel shifts were measured using Image J software and interpreted
with the program Origin 8.0. The fractions (f) for each trimer forming complex was
calculated by dividing the corresponding quantified values for trimers by the total sum of
values for all complexes (monomer, dimer, and trimer) presented in the corresponding
lane. The combined data from several independent measurements were subjected to nonlinear curve fitting using the equation:
(2.1)
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where Ct is the total concentration of RNA strands in each lane and f is the fraction of
3WJ complex to total concentration.
In calculating the Ct, the concentration of the labeled 3WJb strand was not
included, as it was in trace amounts and negligible to the concentrations of 3WJa and
3WJc. The Ct at equilibrium was calculated by interpolation of the fraction (f) at 50%.
These values were then in turn used to calculate the equilibrium KDs (191). Marky et al.
described this calculation using changing temperature to reach equilibrium, thus requiring
equal concentrations of each strand; however, equilibrium was reached here by varying
concentrations, as previous performed (88,196), thus not requiring equal concentrations
of each strand.
Real time PCR annealing curves of 3WJ complexes
Each synthesized pRNA-3WJ strand (3WJa, 3WJb, 3WJc) was mixed at equimolar
concentrations in the presence of 1x SYBR Green II dye (Invitrogen) at equal molar
ratios of 10 μM to create a 3WJRNA, 3WJDNA, and 3WJ2′-F. SYBR Green II dye is a
reporter dye with higher specificity for RNA, but shows binding to both DNA and RNA
bases (197). Using a Roche Lightcycler 480 real time PCR machine, with accurate
readings of temperatures to ± >0.25 °C, samples were heated to 95 °C for 5 min for an
initial denaturing period and then slowly cooled at a rate of 0.11 °C/sec until 20 °C. The
Roche Lightcycler 480 was able to detect the fluorescence levels, thus monitor the
formation of the 3WJ cores. All samples were completed in triplicate to ensure accuracy
of the annealing temperatures and profiles. Samples were then subjected to
electrophoresis on a 12% polyacrylamide gel to ensure the formation of the 3WJs. All
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hybrid structures of the pRNA-3WJ core were created using a mix of RNA/DNA,
RNA/2′-F RNA, or DNA/2′-F RNA in the same method described as above.
TGGE and thermodynamic parameters
All 3WJ hybrids were assembled as described above. The Temperature Gradient
Gel Electrophoresis (TGGE) system from BiometraHmbGh, Germany was used in this
study. Temperature was varied perpendicular or parallel to the electrical current. All
experiments were performed in TMS running buffer. The RNA bands were detected in
native 15% gel by total RNA stain using Ethidium bromide (EB). The concentrations of
3WJs were typically 10 μM. All varieties were run a minimum of three times to ensure
accuracy of measurement.
Various concentrations of preassembled pRNA-3WJs covering 1,000 fold
dilutions from 10 μM to 0.016 μM were subjected to the perpendicular TGGE for
thermodynamic parameter calculations. 3WJ bands were detected with radiolabeled 3WJc
strands at the 5′-end using γ-32P ATP (Perkin Elmer). A linear temperature gradient of
ΔT = 44 °C was applied perpendicular to the electric field. The gels were run for 1 hr at
constant 80 V, dried, and exposed to phosphoroimaging screen overnight. Gels were then
visualized on a Typhoon (GE), and Image J software was used to quantify the area of
bands on each lane by plotting intensity of each band intensity and integrating the area
under the curve for each band. Background signal of each lane immediately surrounding
the band of interest from the gel was subtracted and removed from the band intensity and
not included in calculations. The fraction of 3WJ bands were obtained by subtracting the
area of melted bands from the trimer band. Melting temperatures were then calculated
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from a plot of 3WJ fraction (f) vs. temperature, with f = 0.5 (50%) corresponding to the
Tm.
Calculation of Thermodynamic parameters
Tm values at different concentration of 3WJs were used to calculate
thermodynamic parameters. van’t Hoff plots were generated by plotting the Tm versus the
concentrations of non-self complementary three molecular strands according to a
previous method (191):
∆

°

∆ °

ln

∆ °

(2.2)

where R is the gas constant 1.987 cal mol-1 K-1 , Ct is the total concentration of each
3WJs, and ΔH° and ΔS° are enthalpy and entropy changes, respectively. Under this
method of calculation, the assumption is made that the heat capacity remains unchanged
throughout the entire melting profile.
Fluorescence of pRNA-3WJ-MG aptamer
The assembled unmodified and 2′-F A/C modified 3WJs (1 μM) were mixed with
Malachite green triphenylmethane (2 µM), a non-fluorescent dye that only fluoresces
when bound to the Malachite green binding aptamer, in binding buffer containing 100
mM KCl, 5 mM MgCl2, and 10 mM HEPES (pH 7.4) and incubated at room temperature
for 30 min. The fluorescence was measured using a fluorospectrometer (Horiba Jobin
Yvon; SPEX Fluolog-3), excited at 615 nm, and scanning from 625 to 800 nm for
emission (198).
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RESULTS AND DISCUSSION:
Assembly of the three-way junctions
pRNA three way junctions composed of RNA (3WJRNA), DNA (3WJDNA), and 2′F U/C modified RNA (3WJ2′-F) were assembled using equimolar concentrations of each
strand of the 3WJ. The formation of the pRNA-3WJs in each of the species was
confirmed by 12% native PAGE (Fig. 2.2). A step-wise assembly through the
polyacrylamide gel was observed between the monomer to dimer, and finally to the fully
assembled trimer band indicating the formation of 3WJs. The assembled RNA, DNA, and
2′-F 3WJs products resulted in high yield (> 90%). Any side product is assumed to be
contributed to slight mismatch in strand concentrations loaded during assembly,
preventing all nucleic acid strands from forming into the 3WJ complex. The data are in
agreement with previously reported results of RNA-3WJ assembly (87).
Dissociation constants (KD) measurements of the 3WJs
The KD values of nucleic acids formation are directly related to their stabilities as
more stable complexes require lower concentrations of the components for self-assembly
resulting in a lower KD value. We measured the apparent dissociation equilibrium
constants for RNA, DNA and 2′-F modified RNA 3WJ complexes (Fig. 2.3). For the
3WJRNA and 3WJ2′-F the KD values were found to be 11.4 and 4.5 nM, respectively. For
the 3WJDNA complex this value was about five times higher (47.7 nM). This indicates that
3WJ2′-F and 3WJRNA were the most stable complexes, and the least stable was 3WJDNA.
These results demonstrated that the incorporation of enzymatically resistant DNA or 2′-F
modified RNA strands into the RNA 3WJ motif could increase the resistance of the
complex to RNases. However, while the DNA strands incorporation decreases the
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Figure 2.2. Assembly of pRNA-3WJ core structures. 12% polyacrylamide gels in
native conditions displaying the stepwise assembly of the 3WJ2′-F, 3WJRNA, and 3WJDNA.
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Figure 2.3. Dissociation constant measurements. Electrophoeretic Mobility Shift
Assay (EMSA) of 32P-labeled 3WJb (constant concentration) assembling with increasing
concentrations of 3WJa and 3WJc for RNA, 2′-F RNA, and DNA on 12% polyacrylamide
gels in native conditions. Plot of percentage of 3WJ formed vs. total concentration to
solve for KD of each 3WJ.

25

stability, the 2′-F modified RNA increases the stabilization of the 3WJ complex, as
shown by the lower dissociation constant compared to the 3WJRNA. Therefore, if a
nanoparticle were needed to be constructed with an alternative melting temperature than
the native 3WJRNA, the stability and properties of 3WJRNA motif can be tuned by
alternating the ratio of 2′-F modified RNA and DNA strands to either increase or
decrease the stability, respectively.
Determination of the formation of complex and Ta of DNA, RNA, and 2′-F RNA-3WJs by
rtPCR machine

The thermostability of 3WJs complexes were compared by measuring their
fluorescence intensities as a function of temperature in the presence of SYBR Green II
dye on a Roche 480 Lightcycler to obtain Ta (87). The annealing transitions in Fig. 2.4AC show that the mixture of three strands (3WJa, 3WJb, and 3WJc) produced the highest
annealing temperature compared to any monomer or dimer formation. Within the
assembling profile, the slope of the transitions directly correlates with ΔG°, as the steeper
slope results in a more negative ΔG° values (190,191). These results showed that the
assembly of the 3WJ was preferred over any dimer formation of any two strands in each
of the three species: RNA, DNA, and 2′-F modified RNA.
From each of the transitions obtained by the Roche 480 Lightcycler, the curves of
the each of the completed 3WJ structures were compared (Fig. 2.4D). The 3WJ2′-F was
the most stable with Ta = 69.8 °C, the 3WJRNA was the next stable at 59.3 °C, and the
3WJDNA had the lowest where Ta = 48.9 °C. These results correlated with literature
reported values of overall thermostability for nucleic acids, and followed the order of
stability: 2′-F RNA > RNA > DNA (150,151,199). Surprisingly, from the assembly
profiles of the pRNA-3WJ species, a single annealing temperature was seen, not two.
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Figure 2.4. Assembly curves produced from the Roche 480 Lightcycler using SYBR
green II reporter dye. (a) 3WJRNA, (b) 3WJDNA, (c) 3WJ2′-F, and each of the components
of the 3WJs. (d) The three 3WJ species directly compared, showing the differences in
melting temperatures (Ta).
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This is evidenced by the single slope to the transition profile and hinting that the 3WJ is
forming rapidly with all three strands producing no by-products; whereas, a two-step
association would display a plateau within the melting curve itself or two individual
sloped regions, resulting in two annealing temperatures. These results show the three
stranded motif forming together, and a dimer species was undetectable due to the rapid
3WJ formation. This rapid formation from three fragments to form the pRNA-3WJ is
highly beneficial due to the fact that it allows a high yield of assembly, while permitting
for the construction and assembly of RNA nanoparticles without creating side products as
a result of the dimer formation.
Comparison of stability between DNA, RNA, and 2′-F RNA-3WJs by TGGE
TGGE is common technique to measure Tm of large and complex nucleic acids
(88,200,201). This approach has an advantage over the real time PCR in that it can be
applied to directly measure the Tm of RNA complexes as fractions of RNA versus
temperature with no intercalation dye required.
Melting temperatures of 3WJ complexes were determined by measuring the
decrease in the yield of 3WJs versus temperature (Fig. 2.5). A temperature gradient was
applied perpendicular to the electrical current, with an increasing temperature that
resulted in the melting of the structures in the later lanes. Here, the percent 3WJ complex
was compared to dimer and monomer formations. Tm were determined as 50% of 3WJ
remaining. Any remaining dimers were not considered as a complex, as it was not
complete 3WJ formations. From the resulting gels, melting temperatures were derived for
the 3WJ2′-F, 3WJRNA, and 3WJDNA as 66.5 °C, 57 °C, and 35.2 °C, respectively. The
melting temperatures for the two RNA species were within the range of error from the Tm
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Figure 2.5. Representative 15% native TGGE with temperature gradient
perpendicular of the electrical current. (a) 3WJ2′-F, (b) 3WJRNA, and (c) 3WJDNA; total
3WJ concentration in each lane = 10 µM. (d) and (e) are control gels showing migration
of 3WJRNA (d) before reaching its Tm in the temperature range of 20-40°C and migration
of 3WJDNA (e) in the temperature range of 40-70 °C that is over its Tm. The 3WJ bands
were detected by total nucleic acid stain with EB.
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found by the fluorescence melting curves, but there was a large difference in Tm between
the two methods for the 3WJDNA. This difference between these two methods was
presumably due to differing affinities of SYBR Green II to DNA and RNA stacking bases
(197). Nevertheless, both methodologies produced data that allowed direct comparison of
the stability among 3WJ complexes, and demonstrated the trend that 2′-F RNA had a
higher melting temperature than RNA, and RNA had a higher Tm than DNA.
Within the TGGE melting gels, the dimer species were again undetected in the
melting curves in the 2′-F RNA and RNA 3WJ species, further pointing to the possibility
of the unusual assembly pathway. However, the 3WJDNA seemed to display a dimer
intermediate, which was previously not seen from the PCR melting profiles. We believe
that this difference between the two temperatures is due to the fact that the TGGE
showed the melting profile, while the PCR curves showed the association of the
molecules. Therefore the TGGE system of the DNA species was dissociation down to a
dimer then monomer, possibly due to the fact that DNA was not the natural species of the
pRNA-3WJ and forced the motif into an unnatural conformation. Furthermore, any dimer
species that is seen in radiolabeled gel analysis can be attributed a slight concentration
mismatch between unlabeled individual strands, and were therefore ignored.
Thermodynamic parameters for 3WJs formation
Non-self complementary nucleic acids usually exhibit a linear correlation Tm and
RNA concentration, as the Tm increased with the increase in nucleic acid strands
concentration (146,148,202). The TGGE approach was further applied to measure Tm of
3WJ species as a function of concentration using ~1,000 fold dilution of the 3WJRNA,
3WJ2′-F, and 3WJDNA complexes from 10 μM to 0.016 μM (Fig. 2.6A). Tms were
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Figure 2.6. Calculation of thermodynamic parameter for 3WJs formation. (a)
Representation of native 15 % TGGE for the 3WJ complexes at the lowest concentration
(0.016 μM in each lane). The radiolabeled C strand of corresponding 3WJ complexes
indicated with asterisk ‘*’. Lanes 3WJc* and 3WJc*+3WJa served as controls for
monomer and dimer location. (b) Melting temperature profiles of RNA, 2′-F RNA, and
DNA 3WJs obtained after quantification of the corresponding band from the
perpendicular TGGE at various concentrations. (c) Plots of Tm vs. 3WJ concentrations
(van’t Hoff analysis) evaluated from melting curves of the 3WJ complexes obtained at
different strand concentrations.
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calculated by finding the temperature at which 50% of the nucleic acids were in trimer
formation compared to the total concentration of the bands observed. 3WJ Tms were used
to calculate thermodynamic parameters for three components of non-self complementary
sequences, according to Marky et al. (191). The typical van’t Hoff plots for 3WJ2′-F,
3WJRNA, and 3WJDNA are represented in figure 2.6C. From the obtained ΔH° and ΔS°
parameters the ∆G°37 was calculated using equation 2.3:
∆

°

∆

°

310.15

∆

°

(2.3)

where ΔH° and ΔS° are enthalpy and entropy, respectively, and K is the abbreviation for
Kelvin. All thermodynamic parameters are summarized in table 2.1. Here the data
produced a near linear trend lines with r2 values very near 1.00. Due to this little error is
seen in calculating melting temperatures, samples were repeated in a selective fashion
due to the high number of gels that would be needed. The repeated experiments allowed
for calculation of error in the thermodynamic parameters which remained low. The
results indicated that the most thermodynamically stable was the 3WJ2′-F (ΔG°37 = -36
kcal/mol) complex, followed by 3WJRNA, (ΔG°37 = -28 kcal/mol), and the 3WJDNA
(ΔG°37 = -15 kcal/mol). Based on the parameters of free energy change for RNA and 2′-F
RNA-3WJ assemblies, it can be determined that the energy for these complexes were
favored two-fold compared to the 3WJDNA. The 3WJDNA displayed a more favorable
decreased enthalpy value of ΔH° = -220 kcal/mol, compared to 3WJ2′-F (ΔH° = -200
kcal/mol), and 3WJRNA (ΔH° = -170 kcal/mol). However, the comparison of entropy
parameters resulted in a significant increase for the RNA and 2′-F RNA complexes. The
two RNA species resulted in more negative free energy changes, yet had higher
enthalpies when compared to DNA. This data combined with the increased entropy
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Table 2.1. Thermodynamic parameters for 3WJs
formation.a
1/Tm vs Log (Ct)
ΔS°37

Tmb

(kcal/mol) (kcal/mol)

(e.u.)

(

2'-F RNA

-36 ± 0.45

-200 ± 5.7

-520 ± 17

72.1

RNA

-28 ± 0.58

-170 ± 13

-440 ± 39

60.4

DNA

-15 ± 0.71

-220 ± 25

-650 ± 83

35.2

3WJs

ΔG°37

ΔH°

a

Parameters derived from 15% native TGGE.

b

Tm values for 3WJ strand concentrations of 10-6 M
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°C)

values of the RNA species indicated that the thermodynamic stabilities of the 3WJRNA
and 3WJ2′-F were entropy-driven (Table 2.1).
The findings of more negative ΔG° values for 2′-F RNA and RNA are consistent
with other studies comparing helical DNA, RNA, and 2′-F RNA (150,151,153,199,203).
However, the notion that was RNA entropically driven, compared to DNA in helical
structures appeared less unanimous as the majority report RNAs to be less entropically
favored and that folding is normally driven by a lower enthalpy value (150,151,153,203).
Here it is believed that the 3WJDNA provided a more rigid structure, producing a lower
internal energy or ΔH compared to the RNAs; however, the flexibility of the RNAs
provided more disorder, thus giving strong stability, ease of folding, and a more negative
ΔG°. This entropy driven assembly combined with the one step assembly expresses the
unusual thermodynamic characteristics of the pRNA-3WJ.
Analysis of 3WJ hybrid formations and thermostability
The hybrid composition (2′-F RNA/RNA; RNA/DNA; DNA/2′-F RNA) within
the RNA 3WJs are of great interest due to their ability to maintain the diverse
functionality of structured RNA molecules, while incorporating the chemical stability of
2′-F RNA and DNA. To test for hybrid 3WJ viability, the 2′-F RNA/RNA; RNA/DNA;
DNA/2′-F RNA hybrids of the 3WJs complexes were characterized by parallel TGGE
and fluorescence melting temperature experiments. Using the TGGE, a temperature
gradient was applied in parallel to the electrical current (Fig 2.7). As the samples
migrated through the gel, the temperature increased from 20 °C to 70 °C; therefore,
melting the hybrid structures as they migrated further into the gel. A less stable 3WJ
complex migrates further as the elevated temperature melts the structure to smaller single
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Figure 2.7. Native 15% TGGE of some hybrid 3WJs with temperature gradient in
parallel of the electrical current. As the 3WJs migrated into the gels, weaker structures
melted due to the elevating temperatures, resulting in a more rapid migration; stable
structures migrated at slower rates. Concentration of hybrids in each lane = 10 µM, the
bands were detected by total nucleic acid stain with EB. (a) Hybrids analyzed in linear
temperature gradient of 20 – 40 °C and (b) the same samples but the temperature range
was 40-70 °C.
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strands, thus causing an increased rate of migration and separating the stable hybrids
from unstable hybrids.
The TGGE analysis demonstrates that each hybrid structure forms correctly and is
stable at lower temperature ranges 20-40 °C (Fig. 2.7A). However, at a higher range of
40-70 °C the RNA/DNA and DNA/2′-F RNA-3WJ hybrid structures melted, resulting in
a more rapid migration rate compare to 2′-F RNA/RNA hybrids (Fig. 2.7B). This direct
comparison between hybrid stability demonstrates weakness in the thermostability of
hybrids involving DNA strands. In addition, the 3WJs hybrids followed the general trend
that more strands with 2′-F modifications equate to a higher stability overall. These
results were further confirmed by the melting temperatures produced for each hybrid on
the Roche 480 Lightcycler as shown in figure 2.8 and table 2.2. Combining the TGGE
gels along with the annealing temperatures provided from the fluorescence melting
curves, the data further supports the findings that 2′-F modifications strengthen the
thermostability of the pRNA-3WJ while DNA substitutions only weaken the 3WJ
complex. In this case, even limited modifications lead to a difference in the
thermostability.
MG-aptamer functionality assay and stability
In order to ensure that the added stability of the 2′-F modifications to the pRNA3WJ was true for a functional, more complex RNA nanoparticle, a fluorescence assay
was performed. The pRNA-3WJ used in this study harbored the Malachite Green (MG)
RNA aptamer that binds to Malachite green triphenylmethane dye causing the chemical
to fluoresce (204). Malachite green itself emits very low fluorescence; therefore, a change
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Figure 2.8. Comparison of pRNA-3WJ hybrid structures. Assembly curves produced
from the Roche 480 Lightcycler of the pRNA-3WJ (a) RNA/DNA hybrids, (b) RNA/2′-F
RNA hybrids, and c) DNA/2′-F RNA hyrbids.
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Table 2.2. Annealing temperature for 3WJ hybrid formation.a
2′-F RNA to RNA Ta (°C)

RNA to DNA

Ta (°C)

DNA to 2′-F RNA Ta (°C)

a2'-F/b2'-F/c2'-F

69.8±2.0 aRNA/bRNA/cRNA

59.3±1.7 aDNA/bDNA/cDNA

48.9±3.2

a2'-F/b2'-F/cRNA

65.4±0.1 aRNA/bRNA/cDNA

42.6±2.2 aDNA/bDNA/c2'-F

48.4±1.6

a2'-F/bRNA/c2'-F

64.1±0.2 aRNA/bDNA/cRNA

48.6±1.5 aDNA/b2'-F/cDNA

51.6±0.4

aRNA/b2'-F/c2'-F

65.5±0.2 aDNA/bRNA/cRNA

53.1±0.1 a2'-F/bDNA/cDNA

47.2±1.5

a2'-F/bRNA/cRNA

62.1±0.1 aRNA/bDNA/cDNA

44.5±2.6 aDNA/b2'-F/c2'-F

59.5±0.2

aRNA/b2'-F/cRNA

62.7±0.2 aDNA/bRNA/cDNA

45.9±2.4 a2'-F/bDNA/c2'-F

52.4±0.6

aRNA/bRNA/c2'-F

61.9±0.4 aDNA/bDNA/cRNA

47.3±0.4 a2'-F/b2'-F/cDNA

51.2±1.8

a

Annealing temperatures calculated at 10 µM total strand concentration in TMS
buffer.
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in the fluorescence can be used to confirm binding and complexation between the RNA
aptamer and chemical (69,198,204,205).
It has been previously shown that the MG aptamer remains active in binding
when nucleotides remain unmodified, as well as when using 2′-F cytosine and adenine
modified nucleotides (198). Therefore we constructed the pRNA-3WJ-MG using
unmodified RNA strands and 2′-F A/C modified RNA strands (see Fig. 2.9A for 2D structure).
The resulting particles were then tested for binding to the MG to show the folding and
functionality of the MG aptamer by measuring its fluorescence emissions (Fig. 2.9B). Both
nanoparticles showed almost identical fluorescence values indicating the formation of correctly
folded structures.

Further we used real time PCR to measure the Ta of pRNA-3WJ-MG and 3WJMG2′-F constructs (Fig. 2.9C). The annealing curves show that the 2′-F A/C modified
3WJ resulted in the annealing temperature of 69.7 °C, higher than unmodified RNA
variant with Ta value of 62.8 °C. This is consistent with the trend of increased RNA 3WJ
stability using 2′-F modifications. Thus, the data demonstrate the effectiveness of the
fluorine modifications regardless of the complexity of the structure, while retaining the
functional conformation of the pRNA-3WJ.
CONCLUSIONS:
In this chapter we obtained thermodynamic parameters for the pRNA-3WJ using
real time PCR and TGGE approaches. It was seen that the three fragments existed either
in 3WJ complex or as monomers, with the intermediate of dimers almost undetectable. It
seems that the three fragment can lead to the formation of 3WJ complex efficiently
within a rapid time. It is also found that the formation of the three-component complex
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was governed by entropy, instead of enthalpy, as usually found in RNA complexes. By
combining this beneficial assembly with the improved thermodynamic characteristics by
2′-Fluoro modifications to the pRNA-3WJ stable RNA nanoparticles can be constructed
with a high yield of over 90%for the treatment of cancers and viral infections.
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Chapter 3: Kinetic Evaluation of pRNA-3WJ Folding
This chapter (with some modification) is in submission at Journal of Biological
Chemistry. Special thanks to Dr. Janice Ortega for help and assistance in preparation of
data for figures 3.2, 3.3, 3.5 and Dr. Emil F. Khisamutdinov for help in preparation of
data for figure 3.4.

INTRODUCTION:
The field of RNA nanotechnology has recently undergone rapid expansion mainly
due to the fact that RNA has the simplicity characteristic of DNA yet the versatile
functionality of proteins (86,91,128,157,159,172-175). With the combination of the
advantage of these two materials, RNA can easily be designed and constructed through
bottom-up construction and plays diverse roles (86,97). The wide-ranging functionalities
of RNA makes it a prime candidate for applications in sensing operates (206), logic gate
computional parts (207-214), imaging reagents (215-218), nano-electro-mechanical
devices (219), and therapeutics including the delivery, specific targeting, and treatment of
cancer and viral infections (12,38,86,87,118,123,176-182). The use of RNA as a delivery
vehicle provides several benefits over other systems and technologies. Firstly, RNA
nanoparticles can be produced with known stoichiometry and high reproducibility (12,8688,124-126), as RNA is composed of simple building blocks with predictable secondary
structure. RNA aptamers can be employed for specific targeting of cell groups through
binding to cell surface receptors much like a protein ligand or antibody (113-115).
Furthermore the replacement of protein targeting reagents with nucleic acids prevents the
induction of antibody (113), allowing for repeated administration. RNA nanoparticles are
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typically between 10 and 50 nanometers in size meaning they are retained in the human
body, yet are small enough to pass through cell membranes through endocytosis (6668,68,69,125,126,183). In in vivo testing RNA nanoparticles have shown favorable
pharmacokinetic and biodistribution properties, as they are able to avoid accumulation in
healthy organs and tissues with efficient retention in tumors (87,123), which is further
expanded upon in Chapter 4. Additionally, RNA possesses unique in vivo attributes such
as transcription, termination, splicing and processing allow for in vivo RNA production;
riboswitches (95,96) and ribozymes (92-94) result in in vivo processing and possible
assembly into nanoparticles in cell for special function such as intracellular computation
(207-214)}; RNA can self-assemble without external forces (208); and RNA is stable in
acidic environments allowing for survival in endosome (112). Even with these
advantages, RNA nanotechnology still has many hurdles that it must overcome in order
to be employed in therapeutics. Most notably, RNA is known to have stability issue and
is prone to degradation by RNase that has since been solved through backbone
modifications, such as 2’-Fluoro (189,220), 2’-OMethyl (221), or Locked nucleotides
(222). The dissociation of the self-assembled RNA nanoparticles at low concentrations
and elevated temperatures at in vivo environments makes it obligatory to address the
dynamic and kinetics issues in RNA nanoparticle assembly (120,146,149,150,184-188).
Recently a novel ultra-stable RNA motif was found in the packaging RNA
(pRNA) of the Phi29 dsDNA packaging motor (Fig. 3.1), that has since diminished the
concerns of RNA nanoparticles dissociating at low concentrations found in vivo because
of its unusually high thermostability (87). This motif is a three way junction (3WJ) that
serves as the central core structure of the pRNA and connects the helical domain (192)
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Figure 3.1: Overview of the Phi29 pRNA and the three-way junction (3WJ). (A) i)
Secondary structure of the Phi29 pRNA monomer with the pRNA-3WJ outlined by the
box which connects the helical domain to the interlocking procapsid binding domains. ii)
Secondary structure and sequence of the pRNA-3WJ and the iii) crystal structure of the
pRNA-3WJ. (B) Assembly gel of the pRNA-3WJ from the three short RNA oligo strand
on 12% Native PAGE. The 3WJ (lane 7) shows efficiency of folding and particle
homogeneity before purification.
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with the two interlocking looped regions of the pRNA (193). It has been determined that
the 3WJ serves as the central folding domain and provides the overall high stability seen
in pRNA (87,122). The motif can be formed from three individual RNA oligos at a high
yield even in the absence of metal ions (87). The novelty behind this structure is in the
ease of formation and the produced melting curve with a remarkably low Gibbs free
energy (ΔG) of -28 kcal/mol and a high melting temperature (Tm) of 59.3 °C (223).
Furthermore it has been proven that the pRNA 3WJ allows the inclusion of RNA
functional moieties such as receptor-binding aptamer, siRNA, ribozyme, miRNA or
riboswitch, resulting in the production of functional nanoparticles (87,137,139). The
addition of functional groups did not interfere with the proper folding of the 3WJ or the
added functional moieties (87). Previously, attempts have been made to elucidate the
mechanism for the kinetic stability of the pRNA-3WJ, yet the 3WJ was found to be too
stable to detect its dissociation by the current technology of radioactive chasing (87).
The understanding of the mechanism of assembly of the pRNA-3WJ and the
interaction of the RNA strands is of fundamental importance, but the study of three
component collisions have not been well-studied in chemistry, biology, or material
sciences. Here, we investigated the kinetic properties of the pRNA-3WJ using Surface
Plasmon Resonance (SPR) to study its association and disassociation using bottom-up
construction RNA nanotechniques. We provided real-time examination of three
component collision of the pRNA-3WJ. Through these studies, the pRNA-3WJ proves to
be ultra-stable and only disassociate at extremely low concentration that are atypical to
other well-studied double-stranded RNA or dimeric macromolecules. Furthermore, the
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pRNA central motif relies heavily on each of the three strands for rapid folding and slow
dissociation rates.
MATERIALS AND METHODS:
Oligonucleotides and Assembly of 3WJs
The pRNA-3WJ was constructed from three RNA oligo fragments. RNA strands
were produced by Integrated DNA Technologies (IDT). Assembly of the pRNA-3WJ was
completed by mixing each of the three RNA strands (3WJa, 3WJb, 3WJc) at equal molar
concentrations at room temperature in TMS buffer (50 mM Tris pH = 8.0, 100 mM NaCl,
10 mM MgCl2). Samples were then ran on a 12% native polyacrylamide gel at 100 V for
2 hrs at 4 °C in TBM running buffer (89 mM Tris, 200 mM Borate acid, and 5 mM
MgCl2) to ensure pRNA-3WJ proper size folding.
Surface Plasmon Resonance (SPR) Studies of the pRNA 3WJ
The BioRad ProteOn XPR36 was used to complete real time interaction studies
of the pRNA-3WJ motif. A neutravidin coated HLC chip (BioRad) was used to
immobilize one of the three 3WJ strands with a 5’ biotin labeled strand of the 3WJ.
Several studies were completed by immobilizing the 3WJa and 3WJc strand to the chip
surface, followed by injection and interaction of the remaining two 3WJ strands. All
studies were conducted at room temperature and in TMS buffer (50 mM Tris pH = 8.0,
100 mM NaCl, 10 mM MgCl2) with added 0.1% Tween. RNA strands were injected at a
concentration ranging from 20.0 μM to 78.0 nM at a constant flow rate of 25 μL/min for
a total of 660 sec, making the analyte RNAs in high excess as an association phase
followed by injection of blank TMS buffer for 2700 sec at 25 μL/min as a dissociation
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phase. Real time association and disassociation was observed and displayed into a
histograph of total response (relationship on mass on chip surface) and time.
SPR studies of the pRNA 3WJ dimers
Utilizing a similar approach as the pRNA-3WJ, the formation and dissociation of
dimers from the pRNA-3WJ were analyzed. In order to remain consistent in the studies,
the same concentration gradients were used to examine the formation of two of the three
strands coming together within the three way junction.
Kinetic modeling of Surface Plasmon Data
Data were extracted from the BioRad ProteOn XPR36 and modeled using Igor
Pro 6.37. The association periods of the SPR plots were modeled using a Langmuir
pseudo first-order model consisting of two and three components using the equation 3.1
and 3.2, respectively. The dissociation of all RNA motifs were modeled using a
Langmuir zero-order reaction as shown in equation 3.3.
1

(3.1)

1

(3.2)

(3.3)
Where R is the response of the SPR in terms of t, time in sec. These kinetic models are derived in
Appendix 1. In fitting the data, the global fitting package was used in linking the association and
dissociation of each sample through the kd and Rmax and Ro.

Calculation of time constant (τ) for complex assembly of pRNA-3WJa, 3WJb, and 3WJc
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The time constant (τ) of the pRNA-3WJ core strand was studied through
Electrophoresis Mobility Shift Assays (EMSA). Single strand of the pRNA-3WJ
fragments was radio labeled using 5′-end using γ-32P ATP (Perkin Elmer), denoted with
an asterisk, as previously described (223). The radio labeled oligo was then held at a
constant concentration of 10 nM and incubated over varying time points ranging from 0 –
720 min with completed pRNA-3WJ structure at 100 nM concentrations. Samples were
snap frozen on dry ice and then ran in a 12% polyacrylamide native gel at 100 V for 2 hr
at 4 °C in TBM running buffer. The gel was then imaged by transferring the radio signal
to a phosphor screen for 12 hr at -80 °C and visualized using a Typhoon 7000 (GE). Band
quantification was completed using OriginPro 8.5. The ratio of single strand to 3WJ was
then calculated and plotted against time. The curve was fitted using equation 3.4 below:
3

3

∙

(3.4)

Where t is the time in seconds and τ is the time constant at which 50% of the labeled 3WJ
strand was in single strand state and 50% had replaced unlabeled strand in the 3WJ
complex (196).
RESULTS AND DISCUSSION:
Determination of Kinetic Parameters of the pRNA-3WJ
The BioRad ProteOn XPR36 allows for real time monitoring and analysis of
molecule association and disassociations. Through the real time analysis, we are able to
calculate the disassociation constant (defined as KD) by measuring the rates of the
chemical reactions moving toward the completed 3WJ and the disassociation to single
RNA strands.
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Through classic definitions of kinetics, all chemical reactions are viewed to reach
equilibrium where there is a balance in the production of products and reactants. In the
case of the pRNA three way junction, a single step chemical reaction is described as the
equation below:
3

3

3

→
←

3

(3.5)

and the rate of reaction forming pRNA-3WJ can be written as:
3

3

3

3

(3.6)

Where ka is the rate constant of the reaction moving toward the formation of the pRNA3WJ and the kd is the rate constant of the reaction moving toward the reactants or
individual strands of RNA expressed as M-2s-1 and s-1, respectively. At equilibrium these
rates of reactions forward and backward are equal to each other, creating a balance
between the formation of the pRNA-3WJ and single stranded RNA. Together the two rate
constants can be combined to define the disassociation and association constant.
and

(3.7)

Based on previous experiments it was believed that the pRNA-3WJ was
undergoing a single association and dissociation step following what is seen in equation
3.5 (87,223). Using SPR, association and disassociation of the pRNA-3WJ was examined
by binding the 3WJa strand to the chip surface acting as the ligand followed by coinjecting 3WJb and 3WJc strands acting as analytes. A single transition is seen in the
association over a range of concentrations from 20 μM to 78 nM. As a result the data was
fit with a Langmuir three component pseudo-first order model, solving for the reaction
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rate constants (Fig. 3.2A-B). In these experiments a relatively constant dissociation
averaging to 4.52x10-05 s-1; this value is within what is expected values of biological
samples. However, it was seen that the association rate of the pRNA-3WJ was seen
constant across tested concentrations of 20 to 0.078 μM, thus leading to varying ka values.
This clearly negates first-order chemical reactions and indicates error in the assembly
kinetic parameters.
Calculation of KD of the pRNA-3WJ dimers
In order to confirm RNA/RNA interactions on the SPR chip, dimers of the pRNA3WJ were tested and assembled (Fig. 3.3, Table 3.1). In each of the dimer interactions
(3WJab, 3WJac, and 3WJbc) Proper association and dissociation periods were produced.
Furthermore, once the data was fit with a pseudo-first order Langmuir model, it was seen
that each of the produced kas and kds produced were constant and concentration
independent. This means the pRNA-3WJ dimers were forming properly on the chip
surface. Interestingly, in comparing the association rate constants of each of the dimer
species, the 3WJbc dimer produced the most rapid on rate with a ka of ~1.35x1005 M-1s-1,
this is nearly an order of magnitude higher than either the 3WJab or 3WJac dimers.
Furthermore, one would predict the 3WJab dimer to produce the most rapid association
rate as the dimer helix consists of 9 base pairs compared to the 8 base pairs seen in the
3WJbc dimer (Fig. 3.1A). In comparing the dissociation rate constants (kd) of the dimers,
the 3WJab dimer is seen to be the most stable (~6.78x10-05 s-1) followed by 3WJac with a
kd of ~6.33x10-04 s-1 and finally the weakest dimer being the 3WJbc (~3.95x10-03 s-1). This
indicates the 3WJbc dimer not only would form the quickest by also dissociate the most
rapidly.
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Figure 3.2: Surface Plasmon Resonance (SPR) of the pRNA-3WJ. A) Assembly of
the 3WJ of three component strands. 5’-Biotin labeled 3WJa was first immobilized to the
SPR chip surface. 3WJb and 3WJc strands were mixed at equal, varying concentrations,
ranging from 20 μM to 78 nM, and injected across the chip surface for 330 sec
(association phase). Following the interaction of the 3WJ strands, blank TMS buffer was
injected across the chip surface for 2700 sec (dissociation phase). The association and
dissociation curves were fit using a A) three-component pseudo-first order model. B)
Calculated Kinetic parameters from SPR curve following a three component pseudo-first
order kinetic model. C) SPR assay for pRNA-3WJ under assumption of previous dimer
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formation data. 5’-Biotin labeled 3WJa was first bound to the SPR chip surface. 3WJb and
3WJc strands were mixed at equal, varying concentrations, ranging from 20 μM to 78
nM, were injected across the chip surface for 660 sec followed by blank TMS buffer for
2700 sec. Association and dissociation curves were fit using a two component pseudofirst order model. D) Kinetic parameters from SPR curves following a two-component
pseudo-first order kinetic model.
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Figure 3.3: SPR assay for pRNA-3WJ dimers. Dimer species that make up the pRNA3WJ were examined through SPR at varying concentrations ranging from 20 μM to 78
nM. The injected RNA strand was injected for 660 sec (association phase) followed by
blank TMS buffer for 2700 sec (dissociation phase). The histographs were then fit using a
two-component pseudo-first order Langmuir model for A) bound 5’-Biotin 3WJb and
3WJa, B) bound 5’-Biotin 3WJb and 3WJc, C) bound 5’-Biotin 3WJc and 3WJa.
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Table 3.1: Kinetic parameters of pRNA-3WJ dimer species
ka
Ligand

Analyte (M-1s-1)

kd
ka Error

(s-1)

KD

KA

kd Error

(M)

(M-1)

3WJb
3WJc

3WJa
3WJa

4.18E+04 2.55E+02
3.59E+04 1.37E+03

6.78E-05
6.34E-04

2.71E-07
8.86E-06

2.30E-09 6.73E+08
2.71E-08 6.17E+07

3WJb

3WJc

1.37E+05 6.31E+03

3.95E-03

1.95E-05

2.88E-08 3.49E+07
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Next in hopes of gaining insight in the assembly mechanism of the pRNA-3WJ,
the association rates of the dimer species were compared to the association rate of the
tested three component one step reaction of the pRNA-3WJ. This was completed by
calculating association rates (ka’) by taking the fitted rate constants and multiplying by
the concentration of the studied interaction resulting in an s-1 unit (Table 3.2). It is
important to note that the pRNA-3WJ was multiplied by a concentration squared value
while dimers only by concentration due to the difference in units of the kas. Surprisingly,
it is seen that the pRNA-3WJ produces a rates of reaction on average an order of
magnitude below the 3WJbc dimer. This would indicate the formation of the dimer
species is occurring before the formation of the pRNA-3WJ, thus creating an
intermediate step that was previously not seen through thermodynamic studies (223).
Determination of time constants of each pRNA-3WJ strand
To further gain insight on the formation of a dimer species and the unusual
formation of the shorter 8 base helix between the 3WJb and 3WJc strands, kinetic studies
were completed on each of the individual pRNA-3WJ strands. Using a time based strand
replacement EMSA, time constants were calculated for each of the RNA strands in order
to examine which, if any of the strands, provides the stability to the 3WJ core. The results
show that the 3WJa and 3WJb strands produce a similar τ of 38.89 min and 35.93 min,
respectively, while the 3WJc showed a τ of only 11.81 min (Fig. 3.4). The longer times
for 50% strand replacement of the 3WJa and 3WJb strands suggests that the structure and
property of 3WJc strand is special and unique. Using Ethidium bromide or SYBR Green
staining within gels, the 3WJc is undetectable while both 3WJa and 3WJb are detected
(87). From these studies, it was determined the 3WJa and 3WJb strands were essential for
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Table 3.2: Association and dissociation rates of pRNA-3WJ and its components
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Figure 3.4: Time Constants of 3WJ strands by Electrophoretic Mobility Shift Assays
(EMSA). The half-life of each 3WJ strand in the pRNA-3WJ were calculated by EMSA
using 32P labeled free strands, replacing unlabeled strands on assembled pRNA-3WJ. The
transition of monomer to 3WJ was then plotted and the data was fitted to calculate τ. A)
3WJa, B) 3WJb, C) 3WJc.
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the strong stability of the pRNA-3WJ motif; however, the high reactivity of the 3WJc
strand allows for the rapid association seen in the SPR studies and previous
thermodynamic studies.
Association mechanism of the pRNA-3WJ
Previous studies on the pRNA-3WJ showed that the three RNA fragments
associated very rapidly and the formation of a dimer intermediate was undetected. While
the idea of a one-step association between the three strands seemed highly unlikely it was
believed that the pRNA-3WJ was formed through the initiation by the folding of a dimer
with a very rapid addition of the third RNA strand. Here we have found that in fact the
3WJb and 3WJc strands form a dimer species at a rapid rate, and above what was seen in
the testing all three strands together. Thus we assume and believe that the two analytes
(3WJb and 3WJc) were forming into dimer complex and at equilibrium before being able
to interact with the 3WJa ligand strand on the chip surface. With this idea the pRNA-3WJ
data was re-analyzed to follow a pseudo-first order reaction that would result in an
assembly mechanism of 3WJb + 3WJc ↔ 3WJbc + 3WJa ↔ 3WJabc (Fig. 3.2B). Here the
same dissociation rates were seen as when modeled as a three component system.
Additionally the rates of association were independent of concentrations tested leading to
varying rate constant values. The only reasonable explanation for this occurring is the
real association rate constant is many orders of magnitude below the observed ka and
working concentrations. This means the rate of the reaction for the 3WJbc + 3WJa ↔
3WJabc is occurring so quickly that it cannot be sensed on the SPR due to concentration
restrictions.
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Therefore, it is proposed that the pRNA-3WJ undergoes a two-step reaction, in
which the second reaction takes place immediately following the first at a rate that is too
fast to currently quantify (Fig. 3.5). This high reaction rate is due to the fact that upon the
initiation of the 3WJbc formation the affinity for the 3WJa strand increases significantly
due to the presence of 17 bases for pairing between the two strands, rather than 8 or 9
base pairs of a single strand. This second high speed reaction is therefore rate limited to
the first reaction of forming the 3WJbc dimer, thus in examining the formation of the
pRNA-3WJ a singular step is seen as without the evidence of an intermediate forming.
Furthermore, each strand and helical region of the pRNA-3WJ plays an important role in
the rapid formation and high stability. As discussed earlier from the τ values, we know
the 3WJc strand is highly reactive, this causes results in the highest ka of the 3WJbc dimer.
While the dimer between the 3WJb and 3WJc strands form the quickest, it also displays
the shortest dissociation rate showing that the pRNA-3WJ stability is provided through
other base pairing. The 3WJa and 3WJc strands provide the high stability of the 3WJ as
shown in their long half-lives and the slow kd seen in SPR studies of the 3WJab. However,
while the pRNA-3WJ relies heavily on the 3WJab helix region for its stability, the pRNA3WJ itself is the most stable motif as shown in having the slowest off rate (kd) (Table
3.2). This can be attributed to the fact that if one helical region of the pRNA-3WJ breaks,
the local concentration of the strand is very high compared to what would be seen in
solution, thus initiating an immediate refolding of that helical region as the second half of
the strand is still attached to the pRNA-3WJ. As a result of these kinetic studies, the high
association rate and slow dissociation rate of the pRNA-3WJ results from contributions
of each of the RNA strands resulting in a three component collision.
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Figure 3.5: Proposed Assembly Mechanism of the pRNA-3WJ. A) The pRNA-3WJ
assembles in a two-step mechanism of 3WJb + 3WJc ↔ 3WJbc + 3WJa ↔ 3WJabc, in
which the first assembly of the 3WJbc dimer is rate limiting. As the dimer is formed it
immediately folds into the complete pRNA-3WJ due to the increased base pairing
presented for the 3WJa strand. The second step occurs at an unobservable step, making
the assembly appear as a B) one-step assembly mechanism.
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CONCLUSIONS:
The pRNA-3WJ forms under a two-step assembly mechanism through the 3WJb +
3WJc ↔ 3WJbc + 3WJa ↔ 3WJabc mechanism, in which the 3WJbc dimer formation occurs
at a rate constant of ~1x105 M-1s-1 and the formation of the pRNA-3WJ at a rate that was
unobservable. The resulting motif is more stable than any of its dimers, while each RNA
strand plays an important role in either the association or dissociation of the 3WJ. The
pRNA-3WJ show extra-ordinary stability, and ease of formation without an observable
intermediate, resulting in a stable branched motif that can be used for the construction of
RNA nanoparticles.
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assistance in preparation of data for figures 4.5, Hui Li for assistance with figures 4.7A,
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INTRODUCTION:
Functionality of living organisms is made up by a wide variety of molecules
consisting of DNA, RNA, and proteins. In the past, DNA has been used for its simplistic
and defined structure in biomaterials (224-227), while proteins have extensively been
utilized for their diverse structure and functionalities (228). RNA brings together the
characteristics of the simplicity of DNA and the wide variety of folding structures and
functions of proteins, making it an attractive candidate for use in nanobiotechnology
(91,229). Utilizing RNA in therapies provides several advantages over other
technologies, including: known stoichiometry and defined folding of nanoparticles,
thereby decreasing the possibility of side effects and toxicity (12,86-88). Multiple RNA
moieties can be incorporated such as receptor-binding aptamer (32,33), siRNA (97-99),
ribozyme (92-94), miRNA (100-102), and riboswitch (95,96) through the use of bottom
up self-assembly (86,97). RNA nanoparticles normally are in the 10-50 nm size range,
which is the optimal to pass through cell membranes through cell surface receptor
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mediated endocytosis while still being retained by the body (66-68). Finally, RNA
nanoparticles can prevent antibody detection by being protein free, but maintain their
selectivity using receptor-binding aptamers (113-115). The previous problem of
instability of RNA nanoparticles once hindered the field of RNA nanotechnology (112);
but 2’-Fluoro (2’-F) modifications to uracil and cytosine backbones not only improves
the thermodynamic stability but makes the resulting RNA resistant to RNase degradation
(189,199). With these benefits, a stable RNA nanoparticle would prove to be a beneficial
therapeutic delivery vehicle that could be used in the specific targeting and treatment of
cancers and viral diseases.
Affecting one in every six men and being the second deadliest cancer in men
(behind lung cancer), prostate cancer is a severe disease that affects a wide population.
There are roughly 250,000 new cases of prostate cancer diagnosed each year with 30,000
deaths (American Cancer Society statistics). LNCaP cells are a class of prostate cancer
cells known for being hormone dependent and androgen sensitive for growth (230-232).
Extensive work on prostate cancer therapies has previously been done using LNCaP cells
as they are normally considered a less aggressive cancer (215,233-235). It is beneficial to
use the early stage cancer cells as a target for therapies, as the tumor has not had time to
develop into an aggressive state, is still hormonal dependent, and overall easier to
manage than an hormone independent tumor. This allows for a contained treatment and a
higher chance of successful removal of the disease. Furthermore, it has been shown that
LNCaP tumor cells over express Prostate Specific Membrane Antigen (PSMA) (232,236238), making it an even more attractive target as it can be easily identified from healthy
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prostate cells allowing for a specific targeting and delivery of therapeutics while having
low toxicity effects on normally functioning prostate cells.
Within cancers, it has been found that many microRNA (miRNA) are either down
regulated or over-expressed (239-241). The differences in expression from healthy tissues
have shown adverse downstream effects on many protein expressions, most notably
leading to down-regulation of tumor suppressors and increased anti-apoptotic genes.
LNCaP-FGC prostate cancer cells are known to have miR17 and miR21 play important
roles (242,243), two common miRNAs that have been shown to be directly related to
cancer progression and growth. These two microRNAs lead to the down-regulation of
tumor suppressors such as PTEN and PDCD4 and up-regulation of anti-apoptotic genes
(243-248). The regulation of these important oncogenes could correct the hindered tumor
suppression and sensitize the cells to apoptosis. Recently anti-miRNA LNA sequences
have been developed for miR17 and miR21, resulting in the silencing of their respective
miRNAs (78). However, due to their small size, they display poor biodistribution
characteristics and are easily cleared from the body. Furthermore, the anti-miRNA
sequences naturally lack any targeting ability to specifically deliver to cancer cells.
Previously, a thermodynamically and chemically stable RNA three-way junction
(3WJ) was discovered within the packaging RNA (pRNA) of the phi29 bacteriophage
DNA packaging motor (87). pRNA forms into a hexameric ring on the packaging
connector and consists of two domains, the helical domain and central domain containing
two interlocking loops) (249-252). The two domains are connected together through a
3WJ that has been shown to form from three short RNA oligo strands in the absence of
metal ions (87). The junction also has the ability to harbor RNA moieties off each branch
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while still retaining the central folding structure of the 3WJ as well as the functionality of
the RNA extensions (87). This ultra-stable platform has proven to be a viable scaffold to
carry RNA functionalities for the use in therapeutics in cancers and viral diseases
(87,123,137,139).
Using the pRNA-3WJ, we propose to create a RNA molecule with specific
targeting ability to prostate cancer cells to carry miRNA LNAs (78). Here we report the
use of the pRNA-3WJ for the construction of RNA nanoparticles for the specific
targeting of prostate cancer tumor cells. LNCaP-FGC cells were used as in vitro cell
model and the over-expression of the PSMA in LNCaP-FGC cells was used as a specific
target. Targeting was achieved through the use of the PSMA A9g RNA aptamer that has
been previously developed (253,254), and conjugated onto the pRNA-3WJ through
bottom-up construction. Furthermore, we have conjugated anti-miRNA LNAs as well as
fluorescent tags onto the remaining two branches of the three way junction for
monitoring the binding and entry into the tumor cells. Nanoparticles were successfully
constructed with defined stoichiometry and size that maintained the folding structures of
both the pRNA-3WJ and A9g PSMA aptamer, keeping the functionality of the aptamer.
The molecules further showed specific targeting to LNCaP-FGC cells in vitro through
flow cytometry, cell confocal microscopy, and dual luciferase assays. Dual luciferase
assays and qRT-PCR reported specific knockdown of miR21 and miR17 in LNCaP cells.
Through these studies, we have proven that the combination of the A9g PSMA aptamer
with anti-miRNA LNAs through the pRNA-3WJ into therapeutic nanoparticles, selective
targeting to prostate cancer, specifically LNCaP-FGC cells, can be accomplished,
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providing a vehicle for therapeutical elements like siRNAs, miRNAs, or chemotherapies
for tumor treatments.
MATERIALS AND METHODS:
Design and construction of pRNA-3WJ nanoparticles harboring PSMA binding
aptamer and anti-miRNA LNA
RNA nanoparticles were constructed using a bottom-up approach, as previously
described. Briefly, DNA oligos primers (Integrated DNA Technologies) were used to
create dsDNA templates through polymerase chain reaction (PCR) for each RNA strand.
RNA strands were then transcribed by T7 polymerase in vitro. Additionally 2’-fluoro (2’F) modified cytosine and uracil were used in transcriptions along with an Y639F mutant
T7 polymerase, giving nuclease stability to the RNA strands. The anti-micro RNA LNAs
were synthesized by Exiqon.
Transcribed RNA strands were purified on 8% polyacrylamide gels containing 8
M Urea ran at 120 V for 1.5 hours on TBE running buffer (89 mM Tris-borate, 2 mM
EDTA). RNA bands of interest were excised from the gel using UV shadow on thin layer
chromatography plates and eluted from gel in elution buffer (0.5 M Ammonium Acetate,
0.1 mM EDTA, 0.1% SDS) at 37 °C for a minimum of 3 hours and then precipitated by
ethanol.
RNA nanoparticles were assembled by mixing strands at equal molar
concentrations in TMS buffer (50 mM Tris pH 8.0, 100 mM NaCl, 10 mM MgCl2) and
heated to 80 °C for 5 minutes and slowly cooled over 40 minutes to 4 °C. Assembled
RNA nanoparticles were then purified on 8% polyacrylamide gels at 100 V for 2 hours
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on TBM running buffer (89 mM Tris, 200 mM borate acid, and 5 mM MgCl2) and at 4
°C. Samples were then excised and eluted as described above.
Temperature Gradient Gel Electrophoresis (TGGE) assay for studying thermodynamic
stability of RNA nanoparticles
For TGGE analysis, the experimental setup was adjusted to have a linear
temperature gradient perpendicular to the electric field (BiometraHmbGh). The
temperature gradient was set from 36.0 °C to 80.0 °C. RNA sample (500 nM) was
combined with 6× gel loading buffer and run on 8% native PAGE at 100 V for 1 h. 10
mM MgCl2 was present in both gel and electrophoresis buffer. The nanoparticles
contained a Cy5 fluorophore on the 3WJb strand for monitoring melting and imaged by
Typhoon FLA 7000 (GE Healthcare). The pRNA-3WJ constructs within the total RNA
was analyzed by ImageJ, and the melting curve of the construct was fitted using
nonlinear Sigmoidal fitting. Melting temperatures (Tm) were calculated where 50% of
total RNA concentration was at ssRNA and 50% was in complexed 3WJ form.
Serum stability assay for studying chemical stability of RNA nanoparticles
400 ng of pRNA-3WJ nanoparticle was incubated in TMS buffer containing fetal
bovine serum (FBS, final concentration is 10%). The total volume was 10 µl. Samples
were taken at multiple time points, including 0, 0.25, 0.5, 1, 2, 6, 12, and 24 hours after
incubation at 37 °C. 8% Native TBM PAGE gel electrophoresis was applied to visualize
RNA. After running for 1.5 hr at 4 °C, the gel was stained by ethidium bromide. Images
were taken by Typhoon FLA 7000 (GE Healthcare).
Dynamic light scattering and Zeta potential measurement of RNA nanoparticles
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Apparent hydrodynamic sizes and zeta potential of pre-assembled A9g-3WJ-antimiR21 LNA and A9g-3WJ nanoparticles were measured by a Zetasizer nano-ZS
(Malvern Instrument, LTD). All RNA samples were measures at 2 μM in DEPC H2O and
PBS buffer (137 mM NaCl, 2.7 mM KCl, 100 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) at
25 °C.
Cell Culture
Human prostate cancer cell lines LNCaP-FGC, LNCaP C4-2 and PC-3 (American
Type Culture Collection, ATCC) were grown and cultured in RPMI 1640 medium
(Invitrogen) containing both 10% fetal bovine serum (FBS) and penicillin/streptomycin
in a 37 °C incubator with a 5% CO2 and a humidified atmosphere.
Flow Cytometry assay of PSMA pRNA-3WJ nanoparticles binding to LNCaP-FGC
cells
LNCaP-FGC and PC-3 cells were trypsinized and rinsed with blank RPMI-1640
medium. 100 nM Cy5 labeled A9g-3WJ and the control pRNA-3WJ were each incubated
with 2 × 105 LNCaP-FGC or PC-3 cells at 37 °C for 2 hr. After washing with PBS (137
mM NaCl, 2.7 mM KCl, 100 mM Na2HPO4, 2 mM KH2PO4, pH 7.4), the cells were
resuspended in PBS buffer. Flow Cytometry was performed by the UK Flow Cytometry
& Cell Sorting core facility to observe the cell binding efficacy of the Cy-5 A9g-3WJ
nanoparticles. Analysis was completed using Flowing Software v2.5 (Turku Centre for
Biotechnology).
Confocal Microscopy imaging analyzing RNA nanoparticle binding and entry into
LNCaP-FGC cells
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LNCaP-FGC and PC-3 cells were grown on glass coverslides in RPMI-1640
medium overnight. 100 nM concentration Alexa647 labeled A9g-3WJ and the control
pRNA-3WJ were each incubated with the cells at 37 °C for 2 hr. After washing with
PBS, the cells were fixed by 4% paraformaldehyde and stained by Alexa Fluor® 488
phalloidin (Invitrogen) for cytoskeleton and TO-PRO®-3 iodide (642⁄661) (Invitrogen)
for nucleus. The cells were then assayed for binding and cell entry by Zeiss LSM 510
laser scanning confocal microscope.
Dual Luciferase Assay to analyze delivery of anti-miRNA by pRNA-3WJ nanoparticles
LNCaP-FGC and PC-3 cells were grown on 24-well plates in RPMI-1640
medium until reaching ~80-90% confluency. 100 nM and 50 nM A9g-3WJ-anti miRNA
LNA and the control RNAs including pRNA-3WJ/anti-miRNA-(17 or 21) LNA and
A9g-3WJ were incubated with cells in opti-MEM at 37 °C for 3 hr. As a positive control,
anti-miRNA LNA transfected by RNAi MAX (following standard protocol by
Invitrogen) into cells, while complete nanoparticles were merely incubated with cells.
After incubation with the RNA, cells were washed once with blank RPMI-1640 medium
and then transfected with psi-Check 2 plasmid (Promega) which contains an oncogenic
miRNA targeting sequences at the 3’-UTR region of Renilla Luciferase gene using
Lipofectamine 2000 (Life Technologies). Dual-luciferase assay (Promega) was used to
evaluate the anti-miRNA LNA effects 24 hr post-transfection upon manufacture’s
instruction. Briefly, cells were washed once with PBS and lysed with passive lysis buffer.
The plates were shaken for 30 minutes at room temperature. 20 μL of the lysate were
added to 50 μL of luciferase assay reagent (LAR II) in a luminometer tube and firefly
luciferase activity was measured. Upon addition of 50 μL of Stop & Glo Reagent, control
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measurements of Renilla luciferase activity were then obtained. The Renilla luciferase
activity obtained was then normalized with respect to the Firefly luciferase activity for
determining the average ratio of Renilla to Firefly luciferase activity over several trials.
Results were statistically analyze by an ANOVA two-way test in comparing Renilla
expression to the cell only control and between PC-3 and LNCaP cell lines among each
concentration.
qRT-PCR assay
Two A9g-pRNA-anti-miRNA LNA constructs were assayed for the subsequent
gene up-regulation effects: one harboring anti-miR21 LNA; and, the other harboring antimiR17 LNA.
LNCaP-FGC cells were incubated with 10 and 100 nM of the individual A9g3WJ-anti-miRNA LNA and control RNAs as described above. After 72 hr treatment,
cells were collected and target gene up-regulation effects were assessed by qRT-PCR.
PC-3 cells were used as negative control cell line.
Cells were processed for total RNA using Trizol RNA extraction reagent
following manufacture’s instruction (Life Technologies). The first cDNA strand was
synthesized on total RNA (1 μg) from cells with the various RNAs treatment using
SuperScriptTM III First-Strand Synthesis System (Invitrogen). Real-time PCR was
performed using Taqman Assay. All reactions were carried out in a final volume of 20
μL using Taqman Fast Universal PCR Master Mix and assayed in triplicate.
Primers/probe set for human PTEN and 18S were purchased from Life Technologies.
PCR was performed on Step-One Plus real time PCR system (Applied Biosystem). The
data was analyzed by the comparative CT Method (ΔΔCT Method). Data was statistically
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analyzed by an ANOVA one-way test in comparing values with the cell only control in
each concentration and gene.
Caspase III assay for studying cell viability upon pRNA-3WJ nanoparticle treatment
LNCaP-FGC cells were plated in 24-well plate and incubated with 100 nM A9g3WJ-anti miRNA LNA constructs and control RNAs as described above at 37 °C for 24
hr. A positive control of incubating cells with 5 μM Campothecin for 4 hr at 37 °C was
used. Caspase III signaling was then assayed using Caspase III Assay Kit (BD
Pharmigen) following the standard protocol. Cells were washed in 1× PBS buffer
followed by incubated in 200 μL Cell Lysate Buffer for 30 min on ice. 100 μL of cell
lysate was then incubated with 1 mL of 1× HEPES Buffer and 15 μl Ac-DEVD-AMC
fluorescent substrate and incubated at 37 °C for 1 hr. Fluorescence was the measured
from 420 to 460 nm with an excitation of 380 nm on fluorospectrometer (Horiba Jobin
Yvon; SPEX Fluolog-3). A peak fluorescence at 440 nm was used to analyze Caspase III
signaling.
In vivo biodistribution and tumor targeting of RNA nanoparticles
LNCaP C4-2 cells were cultured in vitro and subcutaneously injected under the
skin of 4 week old male nude mice. A total of 2×106 cells were injected in solution with
Matrigel (Corning) as a 50/50 % blend. Tumors were grown for 4 weeks until tumors
reached a volume of 200 mm3. Mice were then administered PBS (blank control), pRNA3WJ (negative control), and A9g-3WJ each with Alexa647 labels as naked oligos at a dose
of 2 μM at 100 μL through the tail vein. Mice were imaged for whole body fluorescence
at time points 0, 1, 2, 3, 4, and 8 hours with an IVIS imager (Caliper Life Sciences).
Upon the completion of the study, mice were sacrificed, and tumors, hearts, kidneys,
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livers, and brains were collected and imaged by the whole body imager for Alexa647
signal. Additionally, tumors were frozen at ‒80 °C, and sectioned for confocal
microscopy as described above.
Furthermore, tumors were fixed in 4% paraformaldehyde with 10% sucrose in 1x
PBS buffer at 4 °C overnight. Tumor samples were then placed in Tissue-Tek O.C.T.
compound (Sakura Finetek USA, Inc.) for frozen sectioning (10 μm thick). Sectioned
tissue were then stained with DAPI and mounted with ProLong Gold Anti-fade Reagent
(Life Technologies) overnight. Slides were then fluorescently imaged by FluoView
FV1000-Filter Confocal Microscope System (Olympus).
In vivo tumor reduction by anti-miRNA LNA pRNA-3WJ nanoparticles
LNCaP C4-2 cells were grown and subcutaneously injected into 4 week old male
nude mice. 2×106 cells were injected as a 50% cell, 50% Matrigel (Corning) blend into
the flank of the mice with a total of 5 mice hosting 2 tumors each. Xenograft tumors were
monitored until they reached roughly 200 mm3 in volume. Naked RNA nanoparticles
harboring the PSMA A9g aptamer and anti-miRNA LNAs were injected through the tail
vein of mice at a concentration of 20 μM at 100 μL on days 7, 10, 13, 17 and 20 while
monitoring tumor volume and total mouse weight up to day 29.
Western blot of miRNA downstream genes of xenograft tumors
Upon the completion of tumor reduction experiments, mice were sacrificed and
tumors were harvested. LNCaP C4-2 tumors were homogenized in RIPA buffer
containing Protease (ThermoFisher). Total protein concentration was measured by BCA
protein assay (ThermoFisher) against protein standards. 100 μg of total protein from the
tumor was loaded onto TDX FastCast SDS PAGE gels (BioRad) and ran at 100 V for 2
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hr. Gels were transferred onto membranes and stained with PTEN, PDCD4, and β-Actin
antibodies (Cell Signaling) and imaged. β-Actin was used as an internal control and
PTEN and PDCD4 are expressed as a ratio with β-Actin.
RESULTS AND DISCUSSION
Construction of pRNA-3WJ nanoparticles harboring PSMA binding aptamer
An RNA aptamer using 2’-Fluoro modified nucleotides was generated through
SELEX (Systematic evolution of ligands by exponential enrichment) for specific
targeting of PSMA by Lupold et al (253). Furthermore, Rockey et al. rationally truncated
the A9 PSMA aptamer shortening the overall length while keeping the high specificity to
PSMA (254). It is well known that prostate specific membrane antigen is overexpressed
in LNCaP-FGC prostate cancer cells (231,232,255-258). PSMA is an important target
since it is overexpressed in primary prostate tumors as well as metastases in the lymph
nodes (259). Furthermore, PSMA has been shown to be upregulated in tumors after
patients have been treated with common androgen-deprivation therapies (257,260). The
truncated PSMA A9g aptamer was placed onto the pRNA-3WJ, creating a branched
RNA motif to specifically target prostate cancer cells. RNA 3WJs were created with the
PSMA aptamer attached to the 3WJa/3WJc branch in three different orientations (Figs.
4.1, 4.3) in order to test if there is any variation in the aptamer folding once placed on the
pRNA-3WJ. Each of the three variants of the A9g-3WJ displayed proper folding and
sizing on polyacrylamide gels ran in native conditions.
Next the prostate targeting 3WJs were tested for nuclease and thermodynamic
stability. First each of the 2’-F modified A9g-3WJs were incubated with 10% fetal bovine
serum over 24 hours (Fig. 4.2A). Samples were then ran on polyacrylamide gels, where
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Figure 4.1. Design and construction of pRNA-3WJ nanoparticles harboring PSMA
binding aptamer and anti-miRNA LNA. A) The sequence and secondary structure of
bacteriophage phi29 packaging RNA (pRNA). B) 3WJ core of pRNA. C) Design of
pRNA-3WJ nanoparticles harboring PSMA binding aptamer and anti-miRNA LNA. D)
10% native TBM PAGE of A9g-3WJ-anti-miR21 nanoparticle.
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Figure 4.2. The stability and characterization of assembled pRNA-3WJ
nanoparticles harboring PSMA binding aptamer and anti-miRNA LNA. A)
Assessment of chemical stability of A9g-3WJ-anti-miRNA LNA treated with 10% serum
contained cell culture medium in 8% TBM native PAGE. B) Assessment of
thermodynamic stability of A9g-3WJ-anti-miRNA LNA by TGGE assay. Melting profile
of nanoparticle derived from PAGE with sigmoidal fitting of data to find melting
temperature. C) Hydrodynamic sizing and zeta potential measurements of the A9g-3WJanti-miR21 nanoparticle using a Zetasizer nano-ZS.
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Figure 4.3. Flow Cytometry assay for studying specific binding of pRNA-3WJ
nanoparticles on prostate cancer cells. A) Illustration of various design of conjugating
PSMA binding A9g aptamer onto the pRNA-3WJ core. Alexa647 labelled A9g-3WJ RNA
nanoparticles were incubated with B) PSMA+ LNCaP-FGC cells and C) PSMA- PC-3
cells. Nanoparticles indicated positive binding of nanoparticles to LNCaP cells while
avoiding non-specific binding to PC-3 cells.
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the band corresponding to the assembled RNA nanoparticles remained stable throughout
all time points. This data shows the RNA nanoparticles will remain stable during in vivo
applications as RNases are not able to recognize and degrade the fluoro modified nucleic
acids. Furthermore, the thermodynamic stability of the PSMA targeting 3WJ was assayed
using temperature gradient gel electrophoresis. Temperature gradient was applied
perpendicular to the electrical current in order to find the melting temperature of the 3WJ
harboring the aptamer (Fig. 4.2B). Previously the melting temperature (Tm) of 2’-F
modified pRNA-3WJ core was found to be 69.8 °C (223). From the TGGE melting
curve, the melting temperature of the A9g-3WJ was found to be 61.2 °C. Although the
Tm of the aptamer-3WJ complex is less than the 3WJ itself, the still rather high melting
temperature of the nanoparticle indicates the PSMA A9 aptamer does not significantly
hinder the stability of the pRNA-3WJ core, and in fact the 3WJ actually provides added
stability to the PSMA aptamer.
After establishing that A9g-3WJ displayed the high stability previously seen in
the pRNA-3WJ, the targeting 3WJ was expanded to harbor anti-miRNA LNAs for testing
the delivery of therapeutics to LNCaP-FGC cells (Fig. 4.1C). The extended helical
regions off of the unoccupied branch of the 3WJ posed no problem in folding of the RNA
strands, as all completed nanoparticles were assayed on polyacrylamide gels ran in native
conditions (Fig. 4.1D). Assembly gels showed high yield of the folded RNA
nanoparticle, without any side product bands being contributed to mismatch in RNA
concentrations during assembly. Within the assembly gel, two bands were seen from the
A9g-3WJ strand and the A9g-3WJ-anti-miRNA samples, this was attributed to formation
of a self-dimer of the A9g aptamer. Furthermore assembled nanoparticles, A9g-3WJ and
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A9g-3WJ-anti-miR21 LNA, were tested for zeta potential and hydrodynamic size (Fig.
4.2C). Here it was found that the size of the nanoparticles were 3.77 ± 0.59 nm and 4.27
± 0.32 nm, with a zeta potential of -18.0 ± 1.45 mV and -22.87 ± 2.40 mV, respectively.
These values are in line with predictions and previously published results of other RNA
nanoparticles (83,125,126).
Targeting of pRNA-3WJ nanoparticles to LNCaP-FGC cells
In order to test the targeting of the pRNA-3WJ, either a fluorescent Alexa647 or
whole chain labeling with Cy5 fluorophore was placed on the 3WJb strand to allow for
tracking of the RNA nanoparticles created and described above. The A9g-3WJ
nanoparticles were incubated with LNCaP-FGC cells, as well as PC-3 cells (PSMA‒) as a
negative control. Following the RNA incubation and washing steps cells were analyzed
by flow cytometry to confirm the binding of each of the three A9g-3WJs. FACS data
showed each of the designs showed strong binding (>75%) to LNCaP-FGC cells while
the aptamer negative pRNA-3WJ displayed only 6.59% binding (Fig. 4.3). However,
with this high binding it was found that the two designs with hinging aptamers produced
an increased and undesired non-specific binding to PC-3 cells. Therefore connecting the
A9g PSMA aptamer to the pRNA-3WJ directly to the two helical regions of the
3WJa/3WJc branch provided the highest binding to LNCaP-FGC (91.22 %), while having
low non-specific binding to PSMA- PC-3 cell line (11.60 %) (Table 4.1). Flow
cytometry data displayed that the addition of the pRNA-3WJ to the end of the PSMA
A9g aptamer did not interrupt cell binding, and provided a branched scaffold for the
addition of therapeutic elements such as siRNAs, miRNAs, and anti-miRNAs.
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Table 4.1. Summary of flow cytometery binding data
Sample (100nM)

LNCaP

PC-3

3WJ (negative)

6.6%

4.4%

A9-3WJ version 1

91.2%

11.6%

A9-3WJ version 2

77.8%

26.6%

A9-3WJ version 3

82.6%

21.6%

Aptamer (positive)

87.6%

9.2%
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Next, endocytosis entry of the RNA nanoparticles harboring the PSMA A9g
aptamer into LNCaP-FGC cells was examined. In order for proper delivery of
therapeutics and RNA nanoparticles to act as anti-cancer agents, entry into the cells are
required for proper release of therapeutic agents. Alexa647 labeled A9g-3WJ nanoparticles
were incubated with LNCaP-FGC and PC-3 cells, cells were then fixed and the nuclei
and cytoplasm were stained. Confocal microscopy images shows proper binding of the
A9g aptamer to LNCaP cells with very little signal seen on PC-3 cells. Furthermore,
confocal imaging along with Z-axis stacking imaging (Fig. 4.4) confirmed Alexa647 signal
within LNCaP-FGC cells on A9g positive nanoparticles. Additionally, little Alexa647
signal was seen around cells samples without the PSMA aptamer and the signal was only
seen accumulating around the LNCaP cells and not within. This data displays that PSMA
A9g aptamer is not only specifically binding to PSMA+ cells, but entering through
receptor mediated endocytosis as expected. Additionally, cell binding assays were
completed using VCaP (PSMA+) and Jurkat (PSMA-) cell lines to further test the
specificity of the A9g-3WJ nanoparticles (data not shown). Here very similar binding
profiles were seen as with LNCaP and PC-3 cells further confirming the targeting of the
A9g aptamer. With positive detection of nanoparticles in the LNCaP-FGC cells, it is
possible to deliver therapeutics in hopes of leading to apoptosis of LNCaP cells through
RNA interference (RNAi).
Delivery of anti-miRNA LNA to LNCaP-FGC cells
Upon confirmation of PSMA targeting nanoparticles entering into LNCaP-FGC
cells, experiments were expanded to test the delivery of therapeutic components. LNCaPFGC cells are known to overexpress miR17 and express miR21, two common oncomirs
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Figure 4.4. Confocal Microscopy for assaying the binding and internalization of
pRNA-3WJ nanoparticles via PSMA binding aptamer A9g. RNA nanoparticles were
incubated with cell groups then fixed and stained for fluorescent imaging. A) A9g-3WJ to
LNCaP cells. B) A9g-3WJ to PC-3 cells. C) 3WJ control to LNCaP cells. D) A9g
aptamer control to LNCaP cells. Blue: DAPI stained nucleus. Green: Phalloidin-Alexa
488 stained cytoplasm. Red: Alexa 647 labeled RNA nanoparticles. Overlay of 3 signals
with z-axis scanning.
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that are seen in cancers (242,243). These two microRNAs lead to the down-regulation of
tumor suppressors such as PTEN and PDCD4 and up-regulation of anti-apoptotic genes
(243-248). Additionally miR-21 has been shown to promote hormone independency
prostate cancers (261) and enhances the invasiveness of LNCaP cells (262); while miR17
has been proven to promote tumor growth and invasiveness in prostate cancer cells (263).
Therefore, silencing miR17 and miR21 could lead to the sensitization of the LNCaP-FGC
cells leading to apoptosis. Anti-miRNA sequences have been developed to target, and
bind miR17 and miR21, thus blocking their gene silencing roles (78).
These anti-miRNAs were placed onto the PSMA A9g-3WJ by a DNA linker
strand for delivery into LNCaP-FGC cells (83). Incubation studies of the RNA
nanoparticles harboring the PSMA RNA aptamer with the miR17 and miR21 were
completed testing the delivery using Promega’s psi-check2 dual luciferase plasmid. The
transfected plasmid contained sequences for Firefly and Renilla luciferase plasmids with
each plasmid containing the microRNA targeting sequences at the 3’-UTR region of
Renilla luciferase, respectively. Therefore in the native cells, the Renilla expression
would be knocked-out, as the miRNA would bind to plasmid, preventing the translation
of Renilla luciferase proteins, but Firefly expression would remain unaffected. As antimiRNA LNA sequences are delivered to the cells, miR17 and miR21 are knocked-down,
thus resulting in an increased expression of Renilla in the dual luciferase assay.
By incubating RNA nanoparticles with LNCaP and PC-3 cells, miR17 and miR21
knock-down was assayed by the described dual luciferase assay. Data in LNCaP-FGC
cells shows significant increase in Renilla expression in the A9g-3WJ-anti-miRNA LNA
and anti-miRNA LNA transfected samples; however, little effect seen from PSMA
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aptamer negative samples for both miR17 and miR21 (Fig. 4.5A-B). This shows the antimiRNA sequences are being properly delivered to LNCaP-FGC cells by the PSMA A9g
aptamer and processed by RISC. Additionally, studies completed in PC-3 cells showed
significantly less increase in Renilla expression from the A9g-3WJ-anti-miRNA LNA
samples, indicating RNA nanoparticles were selectively targeting LNCaP cells through
PSMA binding, indicating a low toxicity to PSMA- cell lines. Furthermore, due to the
fact that the aptamer sequence is on a different strand from the anti-miRNA sequences,
these studies indicate that the RNA nanoparticles are remaining stable and intact through
the pRNA-3WJ core throughout the studies.
To further confirm the delivery of anti-miRNA LNA sequences into LNCaP-FGC
cells and the ability for the LNAs to effect downstream gene expressions quantitative real
time PCR was completed, examining the expression of PTEN and PDCD4, known
downstream genes of both miR17 and miR21. 18S was used as an internal control during
these experiments to standardize the expressions of PTEN and PDCD4 mRNA. q-rtPCR
results show significant increase of PTEN at only a 10 nM concentration of RNA
nanoparticles in the A9g-3WJ-anti-miR21 samples over the negative controls (Fig. 4.5C).
Additionally it was seen that the RNA nanoparticles were able to slightly increase the
PDCD4 expression slightly over negative controls and the cell only samples. These data
further prove the delivery of anti-miRNA LNAs to LNCaP-FGC cells through the A9g3WJ complex. Furthermore, the increase of tumor suppressor genes not only shows a true
knockdown of the miRNAs, but displays the RNA nanoparticles’ ability to correct errors
in gene expressions caused by the prostate cancer.
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Figure 4.5. Assay for miRNA knockdown and downstream gene regulation effects
of pRNA-3WJ nanoparticles harboring PSMA binding aptamer and anti-oncogenic
miRNA LNA. A) Dual-luciferase assay for evaluating delivered anti-miR21 LNA and B)
anti-miR17 LNA effects on prostate cancer cells from incubation of RNA nanoparticles.
Knockdown of miRNAs led to spiked increase of reporter Renilla expression. C) qPCR
results of downstream genes PTEN and PDCD4 expression as a result of miR21
knockdown in LNCaP cells 72 hours post incubation with A9-3WJ-anti-miR21 LNA
nanoparticles. D) Design of A9g-3WJ-anti miR21 LNA and -anti-miR17 LNA
nanoparticles. In all plots *p<0.1, **p<0.01, ***p<0.001.
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From the confirmed up-regulation of tumor suppressor genes by delivery of
miRNA LNAs by the 3WJ, testing of apoptotic effects were completed through assaying
Caspase III signaling on LNCaP-FGC and PC-3 cells after incubation with A9g-3WJanti-miRNAs along with negative nanoparticle controls described before (Fig. 4.6). The
PC-3 cells and negative RNA nanoparticles with LNCaP cells were used to show the
RNA nanoparticles were not toxic to the cells and apoptosis only occurred through
specific delivery of the anti-miRNA LNAs. A spike in Caspase III signaling was seen in
LNCaP cells treated with A9g-3WJ-anti-miR17 and transfected by RNAi Max antimiRNA LNAs (Fig. 4.6). This indicates that the silencing of miRNA was able to
successfully lead to the death of LNCaP cells. Here apoptosis caused by the decreased
expression of miR17 shows the important role of the miRNA in LNCaP cells and the
ability to control the cell growth and death through its expressions.
Through this data, the prostate cancer targeting RNA nanoparticles delivering the
anti-miRNA LNAs shows the vast possibility of RNA nanoparticles. Here, we show
constructed nanoparticles using the pRNA-3WJ were stable in FBS, being resistant to
RNases and stable at temperatures well above the 37 °C needed for in vivo applications.
Furthermore, the 3WJ harboring the PSMA aptamer and anti-miRNA LNAs and positive
functionality of each shows the versatility of the pRNA-3WJ to harbor RNA moieties
while keeping the original functionality of each of the RNA groups; i.e. the targeting and
binding of the PSMA aptamer and the silencing ability of the anti-miRNA LNAs.
Through these experiments, we have shown that stable RNA nanoparticles can be
constructed for the specific targeting and treatment of cancers, and past hurdles that have
held back the field of RNA nanotechnology are no longer a concern.
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Figure 4.6. Caspase III signaling assay for apoptosis effects of 3WJ-pRNA
nanoparticles harboring PSMA binding aptamer and anti-oncogenic miRNA LNA.
RNA nanoparticles with anti-miR21 and -miR17 LNA were incubated with A) LNCaP
and B) PC-3 cells cells for 24 hours. Caspase III signaling was assayed by fluorescent
reporter with peak fluorescent of 440 nm as a reporter of cell apoptosis as a result of
RNA nanoparticle delivery of anti-miRNA sequences. 5 μM Campothecin was used as a
positive control and benchmark of apoptosis (**p<0.01, ***p<0.001).
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In vivo delivery of anti-miRNA LNA to LNCaP
Subcutaneous xenograft tumors were developed in male nude mice with LNCaP
C4-2 cells. Once tumors were fully developed (2 weeks) with cardio vasculature, 100 μL
of 20 μM solution of pRNA-3WJ nanoparticle harboring the PSMA A9g aptamer along
with an Alexa647 fluorescent tag were administered to the mice through tail-vein
injection. For all in vivo studies, nanoparticles were injected and delivered as bare oligos
without the aid of any additives. Through a series of time points, mice were whole body
imaged to examine the biodistribution of nanoparticles, along with the accumulation in
tumors as well as healthy organs. Initially Alexa647 was detected throughout the whole
body of the mice indicating nanoparticles successfully circulated through the mice.
Through early time points, Alexa647 concentrated in the tumor, liver, and bladder of the
mice; indicating the excess nanoparticles were excreted through the urine. After 8 hours,
fluorescence signal was undetectable in all healthy organs was remaining strong in the
xenograft tumor (Fig. 4.7A). Additionally tumors were sectioned and imaged for
fluorescent imaging (Fig. 4.7C). Confocal imaging shows specific targeting and
accumulation of the A9g-3WJ nanoparticles to the LNCaP xenograft tumor. This
indicates nanoparticles have no lasting accumulation in the liver or kidneys, thus having
low toxicity profiles.
Furthermore the therapeutic effects of the A9g-3WJ-anti-miRNA nanoparticles
were tested in vivo on LNCaP C4-2 subcutaneous xenografts. After tumors were
developed to a volume of ~200 mm3, nanoparticles harboring the anti-miR17 and –
miR21 LNAs were administered to the mice through a series of five tail vein injections.
Tumor volume and total weight of the mice were monitored throughout this experiment.
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Figure 4.7. In vivo delivery of 3WJ-pRNA nanoparticles harboring PSMA binding
aptamer and anti-miRNA LNA. RNA nanoparticles were delivered as bare oligos to
LNCaP C4-2 subcutaneous xenografts in nude mice. A) Biodistribution of A9g-3WJAlexa647 through nude mice. B: Brain, L: Lung, S: Spleen, Lv: Liver, K: Kidney, T:
Tumor. B) Tumor bearing nude mice were administered nanoparticles through a series of
five injections through the tail vein of 20 μM solution at 100 μL (indicated by arrows),
while tumor volume (mm3) and total mouse weight (g) were monitored (*P<0.05,
**P<0.01, ***P<0.0001). C) Fluorescent confocal microscopy of tumor samples 8 hr
post i.v. administration of RNA nanoparticles. DAPI (Blue) is cell nucleus, Alexa647 (red)
is RNA nanoparticle. D) Western blot examining downstream expression of PTEN and
PDCD4 from silencing of miR17 and miR21 using β-Actin as an internal control.
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From the tumor volume data (Fig. 4.7B), it can clearly be seen that the A9-3WJ-antimiRNA samples led to a stunted tumor growth and proliferation compared to negative
controls, thus indicating the anti-miRNA oligos had a profound effect on the tumor
environment and cell growth. Even after post-administration of the nanoparticles, a lack
of growth in the tumors was seen for several days compared to non-treated tumors.
Furthermore, there was no significant change in the mice weights over the observed RNA
nanoparticle delivery indicating no toxicity in the mice and the tumor reduction was as a
result of specific delivery to the tumors.
At the conclusion of in vivo delivery of the pRNA-3WJ nanoparticles, mice were
sacrificed and tumors were harvested. PTEN and PDCD4 expressions were measured in
the tumors, using β-Actin as an internal control. Western blots (Fig. 4.7D) show an
increase in PTEN and PDCD4 in the pRNA-3WJ nanoparticles harboring the antimiRNA LNAs. These results display the same ability of the 3WJ-pRNA nanoparticles as
seen in vitro with the LNCaP cells, as the anti-miRNA sequences led to the increase of
expression tumor suppressor genes as a result of decreased miR21 and miR17
expressions. On average an increase was seen in the A9g-3WJ sample over the control
but less than A9g-3WJ-anti-miRNA groups. This may have been due to the repeated
dosage of the RNA to the tumor cell in the animal trials, the larger volume of the
nanoparticle may have had an effect on the gene expression within the tumor; however,
the change in gene expression was not enough to create a change in tumor growth as
shown in Fig. 4.7B. Here we demonstrate not only the ability of the RNA nanoparticles
to accumulate and target the tumor specifically with high affinity, but deliver antioncogenic RNA sequences to regulate tumor growth and development of tumors.
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CONCLUSIONS
Here we created RNA nanoparticles using the pRNA-3WJ core from the phi29
packaging motor for specific targeting and treatment of prostate cancer cells. RNA
nanoparticles were proven to remain chemically and thermodynamically stable after the
addition of functional groups off each branch. The LNCaP prostate cancer specific
nanoparticles produces excellent binding profiles, displaying binding at over 90% at 100
nM RNA concentrations and later proved to provide specific delivery of anti-miRNA
sequences for the knockdown of miR17 and miR21, two common oncogenes. Significant
knockdown of miR17 and miR21 and up-regulation of PTEN indicated the positive and
specific delivery by the pRNA-3WJ RNA nanoparticles in in vitro and in vivo. Through
these studies, RNA nanoparticles have been developed that have the capability to target
tumors primary and metastatic tumors as well tumors after hormone deprivation
treatments. Furthermore, anti-miRNA sequences have been shown to control tumor
growth and proliferation, while having the possibility to prevent PSMA tumors from
transitioning to hormonal independent states.
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Chapter 5: Future Direction and Current State of the Field

CONCLUSIONS AND FUTURE DIRECTION:
In this thesis work is described for the advancement of the RNA nanotechnology
field. In the past RNA nanoparticles have been limited due to their lack of stability to
nucleases found in the body and their thermodynamic stability. As a result the promises
of RNAi technologies have been ignored and the once strong interest has disappeared.
Here in Chapter 2 and Chapter 3 of this dissertation, the instability of RNA has been
overcome. By using previously developed 2-Fluoro modifications RNAs are now
resistant to nucleases that are found in vivo. From the data here the pRNA-3WJ has
proven to be a thermodynamically stable branched motif allowing for the conjugation of
up to three functional groups. The novel assembly of the pRNA-3WJ of three RNA
strands assembling in a one-step assembly that is entropically favored results in a ultrastable RNA molecule stable to 29.5 pM and 69.8 °C. These findings were then translated
into developing RNA nanoparticles for the specific targeting and delivery of anti-miRNA
therapeutics to LNCaP prostate cancer cells. The pRNA-3WJ produced stable RNA
nanoparticles that resulted in the knock-down of miRNA-21 and -17, ultimately leading
to the apoptosis of the LNCaP cells, while displaying no toxic effects to PSMA- cells.
Here the pRNA-3WJ has proven to be a stable, versatile RNA motif that revives the
previous excitement behind RNAi therapeutics by overcoming previous roadblocks of
instability.
However, in order to fully prove the potential of the pRNA-3WJ and RNA
nanotechnology for the treatment of prostate cancer, future work is need. While it is
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proven that the pRNA-3WJ based nanoparticles can target and treat prostate cancer cells
in vitro and in subcutaneous xenograft tumors, and similar nanoparticles have been tested
on other cancer models in vivo in mice; the PSMA-3WJ-anti-miRNA-21 and -17 need to
be tested in a further tested more extensive mouse models to make proper conclusions for
the applications in humans. It is generally accepted that pRNA-3WJ nanoparticles do not
display any toxic effects or have long lasting accumulation in healthy organs;
characterization of prostate cancer targeting and treatment of a solid prostate cancer
tumor is needed. While a subcutaneous xenograft is a simple animal model to create,
orthotopical models of prostate cancer would provide a more representative tumor model
within mice. This would allow for a more hormonal dependent environment for proper
tumor growth. In testing the RNA nanoparticles should be assayed for targeting and
honing to the tumor developed in the mice as well as monitoring the tumor growth after
treatment of the RNA nanoparticles. Futhermore, it is thought that the targeted miRNA21 and -17 play roles in metastasis of prostate cancer and the created RNA nanoparticles
may be able to control this action. If this is to be true extended studies in mice with a
metastasis model treated with A9g-3WJ-anti-miRNA nanoparticles is to be tested.
Furthermore, it should be confirmed that the RNA nanoparticles do not have any toxic
effects or accumulations in healthy organs within the mice. If the future in vivo testing of
the PSMA-3WJ-anti-miRNA nanoparticles remains as promising as presented here,
further development into clinical trials should be considered.
CURRENT STATE OF THE FIELD:
Since the development of RNA nanotechnology in 1998 (12), the field has come a
long way covering several hurdles that once blocked its progress. With the current growth
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and findings of the most recent research, RNA nanotechnology has a possibility of
bringing the initial promise of RNAi therapeutics to fruition. Previously RNA
nanotechnology was not thought of for the treatment of cancers and viral infections due
to several limitations of RNA, most notably the cost of production, susceptibility to
RNases found in throughout the body, thermodynamic stability and dissociation of the
RNA strands. Progress through the field has overcome most of these limitations.
As described in this dissertation, RNAs have now been proven to remain stable
both against nucleases and dissociation. Chemical modifications to the carbon ring of
RNA has shown to produce nucleic acid structures that are stable against nucleases (189)
and are stable in vivo as shown in mice (87,123,137,139). Additionally these
modifications have also been shown to increase the thermodynamic stability of the RNA
structure (223). The Phi29 pRNA three-way junction motif has been tested and proven to
remain stable at ultra-low concentrations and does not dissociation when placed into
mice. Furthermore, several other RNA nanoparticles have been constructed and shown to
be stable during in vivo testing (264-266). These recent results have shown the RNA
nanotechnology has overcome two previous hurdles blocking the field from growing.
Previously, one of the major limitations of RNA nanotechnology was the cost of
production and limitations to the size of production. RNA is typically produced through
in vitro transcription with T7 RNA polymerase (177,267) or through chemical synthesis.
In vitro transcription of RNAs provides a relatively low cost of production; however, not
only is the process time consuming, the batch size of production is normally limited to a
small scale that is far too small to be used for human dosing. Additionally the production
of RNA through T7 polymerase created some level of error in both the length and
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sequence created, requiring purification of RNA strands to remove off-target, undesired
strands. On the opposite spectrum chemical synthesis provides very specific RNA
products. However, the cost of production of RNA through chemical synthesis was cost
prohibitive in order to produce RNA on a scale needed for clinical testing. Additionally,
the chemical synthesis was limited to synthesizing RNA to sizes below 60 base pairs. The
limitations behind each of the methods thus limited the large scale production of RNAs
needed for clinical trials. However, recent work and efforts have targeted the production
of RNA to lower the cost and increase the scale of production. Chemical synthesis of
RNAs have now increased the length able to be produced and continues to grow.
Additionally large scale production has now been produced to reach up to gram scale
synthesis, while lowering the cost of production. Furthermore, techniques have been
developed for large scale purification of RNAs (268). As technologies advance the
production of RNA for in vivo testing and moving to translational work will only
advance, making RNA nanoparticles a viable product as the cost will continue to
decrease and become more reasonable.
While the field of RNA nanotechnology is considered relatively young compared
to other nanotechnology fields, it has recently proven to be a promising area of research
for the treatment of cancers and viral infections. RNA nanoparticles are now to the point
that they have proven to work and function properly and at a non-toxic level in vitro and
in vivo in animal testing; and are approaching the point in which they will undergo
clinical testing. Methods in large scale production of RNA is now possible to provide the
demand of large amounts of RNA that will be needed for delivery into humans. After
close to two decades of growth, the field of RNA nanotechnology has reached a point in
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which the hurdles that were once limiting the growth have been overcome and now
research and testing of the particles can move forward unhindered.

Copyright © Daniel William Binzel 2016
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APPENDICES
APPENDIX 1: DERRIVATION OF KINETICS MODELS
Association Phase:
In the reaction: 3

3
3

3

3

the rate equation will be as below

3

3

3

3

In solving this reaction it will be assumed that 3WJc is the ligand strand bound to the SPR
chip surface and 3WJa and 3WJb strands are the analyte strands flowing over the chip
surface. In this case, the [3WJa] and [3WJb] are at a much higher concentration than
[3WJc] and the formation of 3WJ will result in no noticeable change in the concentrations
of [3WJa] or [3WJb] therefore:
3

3

and
3

3

3

3

additionally

To solve the differential rate equation, x will be the [3WJc] that has been converted to
[3WJ]. Therefore
3

3

and
3

3

This gives a new differential equation of
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3

3

3

3

Or
3

3

3

Next, at equilibrium the reaction forward forming 3WJ is at the same rate as the reverse
reaction forming ssRNAs; the following equations are true
3

3

3
3

3

3

3

3

3

3

These equilibrium equations can be plugged into the differential equation
3

3

3

Or rearranged to
3

3

3

3

Where the first term is equal to zero at an equilibrium state, resulting in
3
The integration of this differential leads to
3

ln

3

Or
ln

3
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Exponential of both sides leads to
1
Here x is replaced with Response from the SPR which is direct proportion to [3WJ],
expressed as R
1
Solving for Req:
At a steady state of the reaction of ssRNA folding to the pRNA-3WJ, the change in
response is expressed as
0

3

3

Where R is the [3WJ] and Rmax is the maximum 3WJ that can be formed and is limited to
[3WJc]. Therefore,
3

3

R is replaced with Req since the reaction is at steady state
3
3
Dissociation Phase:
The dissociation of the pRNA-3WJ is considered unimolecular and rate of reaction is
expressed as
3

3

Again the [3WJ] is placed in terms of Response from the SPR machine and the rate
differential equation id then expressed as
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The simple differential is then solved through integration to

ln

ln

Taking an exponential on both sides results in

Therefore the SPR curves can be modeled using the following equations for the
association and dissociation phases, respectively.
3
3

1
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